WO2021132462A1 - 補体c5の発現を抑制する二本鎖リボ核酸を含む医薬組成物 - Google Patents
補体c5の発現を抑制する二本鎖リボ核酸を含む医薬組成物 Download PDFInfo
- Publication number
- WO2021132462A1 WO2021132462A1 PCT/JP2020/048441 JP2020048441W WO2021132462A1 WO 2021132462 A1 WO2021132462 A1 WO 2021132462A1 JP 2020048441 W JP2020048441 W JP 2020048441W WO 2021132462 A1 WO2021132462 A1 WO 2021132462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- lipid
- lipid complex
- seq
- composition according
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 147
- 229920002477 rna polymer Polymers 0.000 title claims abstract description 85
- 102100031506 Complement C5 Human genes 0.000 title description 23
- 230000014509 gene expression Effects 0.000 title description 21
- 108010028773 Complement C5 Proteins 0.000 title description 17
- 230000002401 inhibitory effect Effects 0.000 title description 8
- 150000002632 lipids Chemical class 0.000 claims abstract description 295
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 162
- 239000002773 nucleotide Substances 0.000 claims abstract description 159
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 108
- -1 polyethylene Polymers 0.000 claims description 93
- 239000002245 particle Substances 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 79
- 238000003860 storage Methods 0.000 claims description 69
- 108091081021 Sense strand Proteins 0.000 claims description 41
- 229930182558 Sterol Natural products 0.000 claims description 33
- 238000004519 manufacturing process Methods 0.000 claims description 33
- 150000003432 sterols Chemical class 0.000 claims description 33
- 235000003702 sterols Nutrition 0.000 claims description 33
- 230000007935 neutral effect Effects 0.000 claims description 27
- 239000004698 Polyethylene Substances 0.000 claims description 22
- 229920000573 polyethylene Polymers 0.000 claims description 22
- 230000000087 stabilizing effect Effects 0.000 claims description 20
- 230000006641 stabilisation Effects 0.000 claims description 16
- 238000011105 stabilization Methods 0.000 claims description 16
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 12
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 12
- 125000002091 cationic group Chemical group 0.000 claims description 12
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 12
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 10
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 description 116
- 108020004459 Small interfering RNA Proteins 0.000 description 60
- 239000004055 small Interfering RNA Substances 0.000 description 59
- 210000002966 serum Anatomy 0.000 description 35
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 239000000523 sample Substances 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 22
- 230000024203 complement activation Effects 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 230000000295 complement effect Effects 0.000 description 18
- 235000012000 cholesterol Nutrition 0.000 description 17
- 239000003495 polar organic solvent Substances 0.000 description 16
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 229920001223 polyethylene glycol Polymers 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000011259 mixed solution Substances 0.000 description 13
- 239000003085 diluting agent Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 241001494479 Pecora Species 0.000 description 10
- 229920000392 Zymosan Polymers 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 101150069146 C5 gene Proteins 0.000 description 8
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 238000010979 pH adjustment Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 6
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 6
- 101100440311 Homo sapiens C5 gene Proteins 0.000 description 5
- 101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 4
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 4
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 4
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 4
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 4
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101100440312 Mus musculus C5 gene Proteins 0.000 description 4
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 108091030071 RNAI Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 4
- 229940076810 beta sitosterol Drugs 0.000 description 4
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 229960002224 eculizumab Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 238000012750 in vivo screening Methods 0.000 description 4
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 4
- 229940058690 lanosterol Drugs 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 150000008300 phosphoramidites Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 4
- 229950005143 sitosterol Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- RLGUEZHGCPLMOT-UHFFFAOYSA-N 2-[1-(2-butyloctoxy)-1-oxoicosan-10-yl]-1-methylpiperidine-4-carboxylic acid Chemical compound CCCCCCCCCCC(CCCCCCCCC(=O)OCC(CCCC)CCCCCC)C1CC(CCN1C)C(=O)O RLGUEZHGCPLMOT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 2
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- CKTYJEZGJXXJRD-UHFFFAOYSA-N 2-[1-(2-butyloctoxy)-1-oxononadecan-10-yl]-1-methylpiperidine-4-carboxylic acid Chemical compound CCCCCCCCCC(CCCCCCCCC(=O)OCC(CCCC)CCCCCC)C1CC(CCN1C)C(=O)O CKTYJEZGJXXJRD-UHFFFAOYSA-N 0.000 description 2
- JNORNSOQEOGZQC-UHFFFAOYSA-N 2-[1-(3,4-dipropylheptoxy)-1-oxoicosan-10-yl]-1-methylpiperidine-4-carboxylic acid Chemical compound CCCCCCCCCCC(CCCCCCCCC(=O)OCCC(CCC)C(CCC)CCC)C1CC(CCN1C)C(=O)O JNORNSOQEOGZQC-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 2
- 102100032996 C5a anaphylatoxin chemotactic receptor 2 Human genes 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 2
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- HXRUXIQIVFHEMR-UHFFFAOYSA-N O=C(CCCCCCC(CCCCCCCCC)C1N(CCCC1)C)OC(CCCC)CCCCCC Chemical compound O=C(CCCCCCC(CCCCCCCCC)C1N(CCCC1)C)OC(CCCC)CCCCCC HXRUXIQIVFHEMR-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 208000037549 Shiga toxin-associated hemolytic uremic syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000032013 atypical susceptibility to 1 hemolytic uremic syndrome Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 2
- 235000004420 brassicasterol Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-M icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC([O-])=O VKOBVWXKNCXXDE-UHFFFAOYSA-M 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 208000017271 typical hemolytic-uremic syndrome Diseases 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- XONHNHCFBNMSFE-UHFFFAOYSA-N 1-(2-octylcyclopropyl)heptadecan-8-yl 1-methylpiperidine-4-carboxylate Chemical compound CN1CCC(CC1)C(=O)OC(CCCCCCCC1C(C1)CCCCCCCC)CCCCCCCCC XONHNHCFBNMSFE-UHFFFAOYSA-N 0.000 description 1
- DSWZKEIQNHSSNB-QYQHSDTDSA-N 2-[1-[(Z)-2-butylnon-3-enoxy]-1-oxoicosan-10-yl]-1-methylpiperidine-4-carboxylic acid Chemical compound CCCCCCCCCCC(CCCCCCCCC(=O)OCC(CCCC)/C=C\CCCCC)C1CC(CCN1C)C(=O)O DSWZKEIQNHSSNB-QYQHSDTDSA-N 0.000 description 1
- LNQVTSROQXJCDD-KQYNXXCUSA-N 3'-AMP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O LNQVTSROQXJCDD-KQYNXXCUSA-N 0.000 description 1
- UOOOPKANIPLQPU-XVFCMESISA-N 3'-CMP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 UOOOPKANIPLQPU-XVFCMESISA-N 0.000 description 1
- FOGRQMPFHUHIGU-XVFCMESISA-N 3'-UMP Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-XVFCMESISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 1
- KXZPALINFYFOHH-UHFFFAOYSA-N CCCCCCCCCC(CCCCCCC)OC(=O)C1CCN(C)CC1 Chemical compound CCCCCCCCCC(CCCCCCC)OC(=O)C1CCN(C)CC1 KXZPALINFYFOHH-UHFFFAOYSA-N 0.000 description 1
- RFDXDQLOURXOHS-UHFFFAOYSA-N CCCCCCCCCCC(CCCCCCCCC)OC(=O)C1CCN(C)CC1 Chemical compound CCCCCCCCCCC(CCCCCCCCC)OC(=O)C1CCN(C)CC1 RFDXDQLOURXOHS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UOOOPKANIPLQPU-UHFFFAOYSA-N Cytidylic acid B Natural products O=C1N=C(N)C=CN1C1C(O)C(OP(O)(O)=O)C(CO)O1 UOOOPKANIPLQPU-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- 101000904460 Encephalitozoon cuniculi (strain GB-M1) Probable glycerol-3-phosphate dehydrogenase Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091006322 GPR77 Proteins 0.000 description 1
- 208000034706 Graft dysfunction Diseases 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 1
- 101000868001 Homo sapiens C5a anaphylatoxin chemotactic receptor 2 Proteins 0.000 description 1
- 208000021330 IgG4-related disease Diseases 0.000 description 1
- 208000037142 IgG4-related systemic disease Diseases 0.000 description 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- NOVIXJRQMVDXEK-UHFFFAOYSA-N O=C(CCCCCCCCCCC(CCCCCCCCC)C1N(CCCC1)C)OC(CCCC)CCCCCC Chemical compound O=C(CCCCCCCCCCC(CCCCCCCCC)C1N(CCCC1)C)OC(CCCC)CCCCCC NOVIXJRQMVDXEK-UHFFFAOYSA-N 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000021917 activation of membrane attack complex Effects 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- ZDPUTNZENXVHJC-UHFFFAOYSA-N cumingianoside D Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(OP(O)(O)=O)C1O ZDPUTNZENXVHJC-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- ZDPUTNZENXVHJC-UUOKFMHZSA-N guanosine 3'-monophosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O ZDPUTNZENXVHJC-UUOKFMHZSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940055944 soliris Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a pharmaceutical composition containing double-stranded ribonucleic acid (dsRNA) that suppresses the expression of complement C5. More specifically, the present invention relates to a pharmaceutical composition containing a lipid complex containing double-stranded ribonucleic acid that suppresses the expression of complement C5, a method for producing the pharmaceutical composition, and a method for stabilizing the pharmaceutical composition. Regarding.
- dsRNA double-stranded ribonucleic acid
- Proteins called complement include proteins represented by C1 to C9, and these proteins are activated in a chain by three different pathways (classical pathway, lectin pathway, and second pathway). An immune response is triggered.
- C5 the fifth component of complement, is degraded by C5 converting enzyme into C5a and C5b.
- the resulting C5a is called anaphylatoxin and provokes an inflammatory response in various cells via C5aR (CD88) and C5L2 (GPR77).
- the resulting C5b reacts sequentially with C6-C9 to form the final product, the complement membrane attack complex (MAC), which causes lysis and cell thawing of pathogens.
- MAC complement membrane attack complex
- the complement system can have a strong damaging effect on host cells if it is not properly controlled or if it is over-activated.
- Non-Patent Document 1 paroxysmal nocturnal hemoglobinuria
- Non-Patent Document 2 atypical hemolytic urotoxicity syndrome
- Non-Patent Document 3 myasthenia gravis
- Neuromyelitis optica Non-Patent Document 4
- Non-Patent Document 5 For antibody-related renal transplant rejection (Non-Patent Document 5), it has been suggested that inhibition of complement C5 is useful for the treatment or prevention of these diseases.
- Eculizumab (Soliris®), an anti-C5 monoclonal antibody, has high affinity for complement C5 and supplements by inhibiting the cleavage of C5 to C5a / C5b and the concomitant complementation membrane attack complex formation. Suppresses excessive activation of the body.
- eculizumab has been shown to have an inhibitory effect on hemolysis, and is known as a therapeutic agent for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
- Eculizumab is also known as a therapeutic agent for systemic myasthenia gravis (gMG).
- gMG systemic myasthenia gravis
- RNAi RNA interference
- dsRNA double-stranded ribonucleic acid
- RISC RNA-induced silencing complex
- An object of the present invention is a pharmaceutical composition containing a lipid complex containing a novel double-stranded ribonucleic acid for suppressing the expression of complement C5, a method for producing the pharmaceutical composition, and a method for stabilizing the pharmaceutical composition.
- the present invention provides, for example, the following [1] to [81].
- [1] A pharmaceutical composition containing a lipid complex.
- the lipid complex comprises a double-stranded ribonucleic acid having a combination of sense and antisense strands.
- the combination of sense and antisense strands A sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 159, an antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 160, a sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 141, and an antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 142.
- a pharmaceutical composition containing a lipid complex is selected from the group consisting of A pharmaceutical composition in which the pH of the solution of the lipid complex is 5.0 or less or 7.5 or more.
- the lipid complex comprises a double-stranded ribonucleic acid having a sense strand consisting of the nucleotide sequence set forth in SEQ ID NO: 145 and an antisense strand consisting of the nucleotide sequence set forth in SEQ ID NO: 146.
- a pharmaceutical composition in which the pH of the solution of the lipid complex is 5.0 or less or 7.5 or more.
- the pharmaceutical composition according to [1] or [2], wherein the pH of the solution of the lipid complex is 2.0 or more and 5.0 or less or 7.5 or more and 11.0 or less.
- the pharmaceutical composition according to [1] or [2], wherein the pH of the solution of the lipid complex is 5.0 or less.
- the lipid complex With cationic lipids The pharmaceutical composition according to any one of [1] to [27], which comprises a neutral lipid, a polyethylene glycol-modified lipid, and at least one lipid selected from the group consisting of sterols.
- the lipid complex The pharmaceutical composition according to any one of [1] to [28], which comprises a cationic lipid, a neutral lipid, a polyethylene glycol-modified lipid, and a sterol.
- Phospholipids Selected from the group consisting of DOPE, POPE, HSPC, SOPC, POPC, EPC, DMPC, DPPC, DSPC, DAPC, DBPC, DLPC, DOPC, DOPG, DPPG, DSPG, DOPS, DOPE-MAL and sphingomyelin.
- Phospholipids Selected from the group consisting of DOPE, HSPC, DPPC, DSPC and DAPC, The pharmaceutical composition according to [33] or [34].
- Polyethylene glycol-modified lipids PEG2000-DMG, PEG2000-DPG, PEG2000-DSG, PEG5000-DMG, PEG5000-DPG, PEG5000-DSG, PEG-CDMA, PEG-C-DOMG, PEG-DAG, PEG-DAA, PEG-phospholipids, PEG-cholesterol And selected from the group consisting of PEG-ceramide (Cer), The pharmaceutical composition according to any one of [28] to [36]. [38] Polyethylene glycol-modified lipids Selected from the group consisting of PEG2000-DMG, PEG2000-DPG, PEG2000-DSG, PEG-CDMA and PEG-C-DOMG.
- [39] The pharmaceutical composition according to any one of [28] to [38], wherein the polyethylene glycol-modified lipid is PEG2000-DMG.
- Sterols Selected from the group consisting of cholesterol, dihydrocholesterol, lanosterol and ⁇ -sitosterol, The pharmaceutical composition according to any one of [28] to [40].
- the lipid complex comprises 2- ⁇ 9-oxo-9-[(3-pentyloctyl) oxy] nonyl ⁇ dodecyl 1-methylpiperidine-4-carboxylate, DSPC, PEG2000-DMG and cholesterol.
- the pharmaceutical composition according to any one of [1] to [42].
- the molar ratio of cationic lipid / neutral lipid / polyethylene glycol-modified lipid / sterol in the lipid complex is 30 to 90 / 0.1 to 20/0.01 to 10 / 0.1 to 70. , [1] to [43].
- the molar ratio of cationic lipid / neutral lipid / polyethylene glycol-modified lipid / sterol in the lipid complex is 40 to 70/3 to 15 / 0.1 to 3/15 to 60, [1].
- the pharmaceutical composition according to any one of [43].
- a method for treating paroxysmal nocturnal hemoglobinuria which comprises administering the pharmaceutical composition according to any one of [1] to [49] to a patient in need thereof.
- a method for treating atypical hemolytic uremic syndrome which comprises administering the pharmaceutical composition according to any one of [1] to [49] to a patient in need thereof.
- a production method comprising the step of adjusting the pH of a solution of a lipid complex to 5.0 or less or 7.5 or more.
- the method for producing a pharmaceutical composition according to any one of [1] to [55]. which comprises the step of adjusting the pH of the solution of the lipid complex to 7.5 or more and 9.0 or less.
- the method for producing a pharmaceutical composition according to any one of [1] to [55]. which comprises the step of adjusting the pH of the solution of the lipid complex to 7.5 or more and 8.5 or less.
- a step of mixing an aqueous solution containing a double-stranded ribonucleic acid having a combination of a sense strand and an antisense strand to obtain a mixed solution is included.
- [67] The method for producing a pharmaceutical composition according to [1] to [55].
- the production method according to [66] further comprising a step of removing the organic solvent from the mixed solution.
- a stabilizing method comprising adjusting the pH of a solution of a lipid complex to 5.0 or less or 7.5 or more.
- the method for stabilizing a pharmaceutical composition according to any one of [1] to [55] which comprises a step of adjusting the pH of a solution of a lipid complex to 5.0 or less, according to [68].
- [71] The method for stabilizing a pharmaceutical composition according to any one of [1] to [55], which comprises a step of adjusting the pH of a solution of a lipid complex to 2.0 or more and 5.0 or less.
- [72] The method for stabilizing a pharmaceutical composition according to any one of [1] to [55], which comprises a step of adjusting the pH of a solution of a lipid complex to 7.5 or more, according to [68].
- the method for stabilizing a pharmaceutical composition according to any one of [1] to [55] which comprises a step of adjusting the pH of a solution of a lipid complex to 7.5 or more and 11.0 or less.
- the stabilization method according to [68] which comprises the step of adjusting the pH of the solution of the lipid complex to 7.5 or more and 10.0 or less.
- the stabilization method according to [68] which comprises the step of adjusting the pH of the solution of the lipid complex to 7.5 or more and 9.5 or less.
- the stabilization method according to [68] which comprises the step of adjusting the pH of the solution of the lipid complex to 7.5 or more and 9.0 or less.
- a step of mixing an aqueous solution containing a double-stranded ribonucleic acid having a combination of a sense strand and an antisense strand to obtain a mixed solution is included.
- the stabilization method according to any one of [68] to [79], wherein the method for stabilizing the pharmaceutical composition is a method for suppressing fluctuations in the average particle size of the lipid complex in the pharmaceutical composition.
- the stabilization method according to [80] wherein the method of suppressing the fluctuation of the average particle size is the method of suppressing the increase of the average particle size.
- a pharmaceutical composition containing a novel double-stranded ribonucleic acid that suppresses the expression of complement C5 a method for producing the pharmaceutical composition, and a method for stabilizing the pharmaceutical composition.
- the pharmaceutical composition according to the present invention has an action of suppressing the expression of complement C5 and suppressing hemolysis, it is a therapeutic agent for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic urinary syndrome (aHUS). Has the potential to be used as.
- PNH paroxysmal nocturnal hemoglobinuria
- aHUS atypical hemolytic urinary syndrome
- Examples of the gene encoding complement C5 targeted by the double-stranded ribonucleic acid according to the present embodiment include, but are not limited to, C5 derived from humans, mice and monkeys.
- the sequence information of the C5 gene can be obtained from public databases in which sequence information is registered, such as GenBank provided by the National Center for Biotechnology Information (NCBI) in the United States, and the nucleotide sequence information of C5 of closely related animal species. It is possible to obtain it by designing a primer based on the above and cloning it from RNA extracted from a desired animal species.
- the C5 gene does not mean a gene having a specific sequence, and includes, for example, a naturally occurring C5 gene having a single nucleotide polymorphism.
- the double-stranded ribonucleic acid having a sense chain and an antisense chain has a sense chain and an antisense chain combination consisting of the nucleotide sequence shown in SEQ ID NO: 13 and the nucleotide sequence shown in SEQ ID NO: 14. From the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 159, the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 160, the sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 115, and the nucleotide sequence shown in SEQ ID NO: 116.
- the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 117 From the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 117, the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 118, the sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 119, and the nucleotide sequence shown in SEQ ID NO: 120.
- the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 121 From the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 121, the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 122, the sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 123, and the nucleotide sequence shown in SEQ ID NO: 124.
- the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 125 From the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 125, the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 126, the sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 127, and the nucleotide sequence shown in SEQ ID NO: 128.
- the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 129 From the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 129, the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 130, the sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 131, and the nucleotide sequence shown in SEQ ID NO: 132.
- Antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 143 and the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 144, nucleotide shown in SEQ ID NO: 145.
- siRNA-008 siRNA-08-01, siRNA-08-02, siRNA-008-08, siRNA-008-09, siRNA-008-10, siRNA-008-11, siRNA in the present specification.
- the double-stranded ribonucleic acid is paired with a sense strand and an antisense strand of any combination of (1) to (21) below.
- (2) Sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 159, and the nucleotide shown in SEQ ID NO: 160 is paired with a sense strand and an antisense strand of any combination of (1) to (21) below.
- antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 126
- Antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 127
- antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 128.
- Sense chain (10) Sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 129, and antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 130 (11)
- Sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 131, and SEQ ID NO: 132.
- Sense chain consisting of nucleotide sequence, antisense chain consisting of nucleotide sequence shown in SEQ ID NO: 142 (16) Sense chain consisting of nucleotide sequence shown in SEQ ID NO: 143, and antisense chain consisting of nucleotide sequence shown in SEQ ID NO: 144 (17) ) Nucleochi shown in SEQ ID NO: 145 The sense strand consisting of the sequence and the antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 146 (18) The sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 147 and the antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 148 (19) ) From the sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 149 and the antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 150 (20) From the sense strand consisting of the nucleotide
- the combination of the sense strand and the antisense strand of (1) to (21) above includes regions complementary to each other.
- the double-stranded ribonucleic acid having the above (1) which is a combination of the sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 13 and the antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 14, contains the following complementary strand. (See Table 1 for details, excluding dT ⁇ dT at the 3'end, respectively). 5'-uGGuAuAuGuGuuGcuGAu-3'(SEQ ID NO: 13) 3'-AcCAuAuAcAcAacGAcUA-5' (SEQ ID NO: 14)
- the double-stranded ribonucleic acid having a sense chain and an antisense chain has a sense chain and an antisense chain combination consisting of the nucleotide sequence shown in SEQ ID NO: 159 and the nucleotide sequence shown in SEQ ID NO: 160. From the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 139, the antisense chain consisting of the nucleotide sequence shown in SEQ ID NO: 140, the sense chain consisting of the nucleotide sequence shown in SEQ ID NO: 141, and the nucleotide sequence shown in SEQ ID NO: 142.
- siRNA-008-01 Selected from the group consisting of antisense chains consisting of.
- siRNA-008-01 Selected from the group consisting of antisense chains consisting of.
- siRNA-008-01 Selected from the group consisting of antisense chains consisting of.
- siRNA-008-01 Selected from the group consisting of antisense chains consisting of.
- siRNA-008-31 siRNA-008-32
- siRNA-008-33 siRNA-008-34
- siRNA-008-35 siRNA-008-. It corresponds to each of the 38 sequences.
- the double-stranded ribonucleic acid having a sense chain and an antisense chain has a sense chain and an antisense chain combination consisting of the nucleotide sequence shown in SEQ ID NO: 159 and the nucleotide sequence shown in SEQ ID NO: 160.
- siRNA-008-01 corresponds to the sequences of siRNA-008-01, siRNA-008-32, siRNA-008-33, siRNA-008-34, siRNA-008-35, and siRNA-008-38, respectively, in the present specification. To do.
- the double-stranded ribonucleic acid having a sense chain and an antisense chain has a sense chain and an antisense chain combination consisting of the nucleotide sequence shown in SEQ ID NO: 141 and the nucleotide sequence shown in SEQ ID NO: 142.
- the double-stranded ribonucleic acid having a sense strand and an antisense strand has a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 159 and an antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 160.
- the above combination corresponds to the sequence of siRNA-008-01 herein.
- the double-stranded ribonucleic acid having a sense strand and an antisense strand has a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 141 and an antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 142.
- the above combination corresponds to the sequence of siRNA-008-32 herein.
- the double-stranded ribonucleic acid having a sense strand and an antisense strand has a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 143 and an antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 144.
- the above combination corresponds to the sequence of siRNA-008-33 herein.
- the double-stranded ribonucleic acid having a sense strand and an antisense strand has a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 145 and an antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 146.
- the above combination corresponds to the sequence of siRNA-008-34 herein.
- the double-stranded ribonucleic acid having a sense strand and an antisense strand has a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 147 and an antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 148.
- the above combination corresponds to the sequence of siRNA-008-35 herein.
- the double-stranded ribonucleic acid having a sense strand and an antisense strand has a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 153 and an antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 154.
- the above combination corresponds to the sequence of siRNA-008-38 herein.
- the antisense strand is substantially complementary to at least a portion of the mRNA transcript of the C5 gene.
- substantially complementary means not only the case where it is completely complementary to the mRNA transcript of the C5 gene, but also the case where it contains one to several acceptable mismatches.
- the sense strand is substantially complementary to at least a portion of the base sequence of the antisense strand.
- substantially complementary means not only the case of being completely complementary to the base sequence of the antisense strand, but also the case of containing one to several allowable mismatches. If the longer oligonucleotide of the sense strand or the antisense strand contains a base sequence that is completely complementary to the shorter oligonucleotide, it can also be expressed as "fully complementary".
- the double-stranded ribonucleic acid also includes modified nucleotides, as described below (see also Table 1). Therefore, in the present specification, nucleotides include not only guanosine-3'-phosphate, cytidine-3'-phosphate, adenosine-3'-phosphate and uridine-3'-phosphate, but also various modified nucleotides. Used to include.
- double-stranded ribonucleic acid or “dsRNA” is a ribonucleic acid (RNA) molecule having a double-stranded structure containing two antiparallel and substantially complementary oligonucleotides, or a ribonucleic acid (RNA) molecule thereof. Refers to a complex.
- examples of the double-stranded ribonucleic acid include, but are not limited to, siRNA (small interfering RNA).
- the double-stranded ribonucleic acid according to the present embodiment has a sense strand and an antisense strand.
- RNAi using the double-stranded ribonucleic acid according to the present embodiment degrades the mRNA of the C5 gene as a target mRNA molecule in the RISC complex, and as a result, the expression of C5 is suppressed. For example, it suppresses the expression of C5 in the target cells.
- the double-stranded ribonucleic acid according to the present embodiment includes a method using chemical synthesis known in the art (for example, described in Nuclear Acid Research, 35 (10), 3287-96 (2007)), an enzymatic transcription method, and the like. Can be synthesized by.
- the double-stranded ribonucleic acid according to this embodiment includes various modifications.
- the modification can be performed by a method known in the art.
- Examples of the modification include sugar modification.
- sugar modification examples include modification of the ribose moiety constituting the ribonucleoside, which includes substitution or addition at the hydroxy group at the 2'position. Specifically, for example, the hydroxy group is substituted with a methoxy group2. Included are'-O-methyl modified nucleotides.
- the nucleotides represented by lowercase letters a, u, g and c represent 2'-O-methyl modified nucleotides, and the sense strand and antisense strand of the double-stranded ribonucleic acid according to the present embodiment are: Contains 2'-O-methyl modified nucleotides.
- the double-stranded ribonucleic acid is modified by inserting an additional nucleotide or nucleotide derivative called an overhang on the 3'or 5'side of the region where the sense strand and the antisense strand form a duplex. You can also do it.
- the double-stranded ribonucleic acid according to the present embodiment has deoxy-thymidine (dT) at the 3'end of the sense strand and the antisense strand as in SEQ ID NO: 13 and SEQ ID NO: 14, and as in SEQ ID NO: 129. , Includes those with reversely bound deoxy-thymidine (idT).
- U and A and the like are added as overhang sequences, for example, UUUU is added to the 3'end of the antisense strand as in SEQ ID NOs: 140 and 142. Including those that have been made.
- the double-stranded ribonucleic acid can also be skeletally modified by modifying or substituting the phosphodiester bond. Modifications or substitutions of phosphodiester bonds include, for example, phosphorothioate bonds.
- the double-stranded ribonucleic acid according to the present embodiment also includes those in which adjacent nucleotides are present via a phosphorothioate bond, such as SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 121.
- the pharmaceutical composition according to this embodiment contains a lipid complex containing double-stranded ribonucleic acid.
- the lipid complex is selected from the group consisting of I) the above double-stranded ribonucleic acid, (II) cationic lipid, (III) neutral lipid, polyethylene glycol modified lipid (PEG lipid) and sterol. Contains at least one type of lipid.
- examples of the lipid complex include, but are not limited to, LNP (lipid nanoparticles).
- the pharmaceutical composition comprises a lipid complex encapsulating double-stranded ribonucleic acid.
- a pharmaceutical composition according to another embodiment comprises lipid nanoparticles comprising double-stranded ribonucleic acid.
- the form of the lipid complex formed by a lipid containing a cationic lipid and double-stranded ribonucleic acid is, for example, a membrane (reverse micelle) composed of double-stranded ribonucleic acid and a single lipid (single molecule) layer.
- a membrane reverse micelle
- examples thereof include a complex, a complex of double-stranded ribonucleic acid and a lipid, a complex of double-stranded ribonucleic acid and a micelle, and the like.
- the double-stranded ribonucleic acid is encapsulated in fine particles composed of a lipid containing a cationic lipid.
- the lipid complex comprises, for example, 0.01-50% by weight, 0.1-30% by weight or 1-10% by weight of the double-stranded ribonucleic acid relative to the total weight of the lipid complex. contains.
- a cationic lipid is an amphipathic molecule having a lipid affinity region containing one or more hydrocarbon groups and a hydrophilic region containing a polar group that protonates at a specific pH.
- the cationic lipid according to the present embodiment is not particularly limited, but for example, the cations described in International Publication No. 2015/105131, International Publication No. 2016/104580, and International Publication No. 2017/222016.
- Sexual lipids can be used, and cationic lipids described in International Publication No. 2016/104580 or International Publication No. 2017/222016 with improved bioresolution can be used.
- Examples of the cationic lipid according to one embodiment include 1-oxo-1- (undecane-5-yloxy) nonadecan-10-yl-1-methylpiperidin-4-carboxylate and 1-((2-butyloctyl). ) Oxy) -1-oxononadecan-10-yl-1-methylpiperidin-4-carboxylate, 1-oxo-1- (undecane-5-yloxy) heptadecane-8-yl-1-methylpiperidin 4-carboxylate, 21-oxo-21- (Undecane-5-yloxy) Henicosan-10-yl-1-methylpiperidin 4-carboxylate, 21- (octane-3-yloxy) -21-oxohenikosan-10-yl-1 -Methylpiperidin-4-carboxylate, 1-((2-butyloctyl) oxy) -1-oxoicosan-10-yl-1-methylpiperidin-4-car
- the cationic lipids are 1-((2-butyloctyl) oxy) -1-oxoicosan-10-yl-1-methylpiperidin-4-carboxylate, 1-((2-butyloctyl) oxy).
- the cationic lipid is 2- ⁇ 9-oxo-9-[(3-pentyloctyl) oxy]
- the lipid complex comprises the above-mentioned cationic lipids, for example, 10-100 mol%, 20-90 mol%, 30-90 mol%, or 30-90 mol%, based on the total lipid contained in the lipid complex. Contains 40-70 mol%.
- the cationic lipid one type may be used alone, or two or more types may be mixed and used.
- the lipid complex comprises, as the lipid component, (I) the above-mentioned cationic lipid and (II) at least one lipid selected from the group consisting of neutral lipids, polyethylene glycol-modified lipids, and sterols. Contains.
- the lipid complex according to the present embodiment contains, for example, 50 to 99.99% by weight, 70 to 99.9% by weight, or 90 to 99% by weight of the lipid component with respect to the total weight of the lipid complex.
- Neutral lipids mean lipids that are present at physiological pH in either the form of uncharged or neutral zwitterions.
- Examples of the neutral lipid according to the present embodiment include phospholipids and ceramides.
- Examples of the phospholipid according to the present embodiment include DOPE (1,2-Dioleoyl-sn-gycero-3-phosphatidylamine), POPE (1-Palmitoyl-2-oleoyl-sn-gycero-3-phosphatidylamine), and HSPC ( Hydrogenated soybean phosphatidylcholine), SOPC (1-Stairoyl-2-oleoyl-sn-gycello-3-phosphatidylline), POPC (1-Palmitoyl-2-olephogylgolphogyl-sn-physepholine) (1,2-Dipalmitoyl-sn-gycero-3-phosphatidine), DPPC (1,2-Dipalmitoyl-
- the triglyceride is DOPE, HSPC, DPPC, DSPC or DAPC. In certain embodiments, the triglyceride is DSPC.
- Neutral lipids can be used alone or in admixture of two or more.
- the lipid complex comprises neutral lipids, eg, 0-50 mol%, 0-40 mol%, 0-30 mol% or 0-20, based on the total lipid contained in the lipid complex. It may contain mol%. In another embodiment, the lipid complex may contain, for example, 0.1 to 20 mol% or 3 to 15 mol% of neutral lipids, based on the total lipids contained in the lipid complex.
- Polyethylene glycol-modified lipid is a lipid having a polyethylene glycol group.
- examples of the polyethylene glycol-modified lipid (PEG lipid) according to one embodiment include PEG2000-DMG, PEG2000-DPG, PEG2000-DSG, PEG5000-DMG, PEG5000-DPG, PEG5000-DSG, PEG-CDMA, and PEG-C-.
- DOMG, PEG-DAG, PEG-DAA, PEG-phospholipid, PEG-cholesterol, PEG-ceramide (Cer) and the like can be mentioned.
- the polyethylene glycol modified lipid is PEG2000-DMG, PEG2000-DPG, PEG2000-DSG, PEG-CDMA or PEG-C-DOMG.
- the polyethylene glycol modified lipid is PEG2000-DMG.
- the PEG also includes methoxy PEG (MPEG).
- MPEG methoxy PEG
- PEG2000-DMG includes MPEG2000-DMG
- PEG2000-DPG also includes MPEG2000-DPG.
- the polyethylene glycol-modified lipid may be used alone or in combination of two or more.
- the lipid complex comprises polyethylene glycol modified lipids, eg, 0-30 mol%, 0-20 mol%, 0-10 mol% or 0. It may contain 5 to 2 mol%. In another embodiment, the lipid complex may contain, for example, 0.01-10 mol% or 0.1-3 mol% of polyethylene glycol modified lipid, based on the total lipid contained in the lipid complex. Good.
- Sterol is an alcohol with a steroid skeleton.
- examples of the sterol according to the present embodiment include cholesterol, dihydrocholesterol, lanosterol, ⁇ -sitosterol, campesterol, stigmasterol, brassicasterol, ergosterol, fucosterol, and 3 ⁇ - [N- (N', N'-). Dimethylaminoethyl) carbamoyl] cholesterol (DC-Chol) and the like.
- the sterol is cholesterol, dihydrocholesterol, lanosterol or ⁇ -sitosterol.
- the sterol is cholesterol.
- Sterols can be used alone or in admixture of two or more.
- the lipid complex may contain, for example, 0-90 mol%, 10-80 mol% or 20-40 mol% of sterols based on the total lipid contained in the lipid complex. In another embodiment, the lipid complex may contain, for example, 0.1-70 mol% or 15-60 mol% sterols based on the total lipids contained in the lipid complex.
- the combination of lipid components in the lipid complex is not particularly limited, and for example, the combination of the above-mentioned cationic lipid, triglyceride and sterol, the above-mentioned cationic lipid, neutral lipid, polyethylene glycol-modified lipid. And a combination of sterols and the like.
- the lipid complex comprises a cationic lipid, a neutral lipid, a polyethylene glycol modified lipid and a sterol. It has been reported that cationic lipids are necessary for encapsulation of nucleic acids and efficient delivery of nucleic acids into target cells, and polyethylene glycol-modified lipids are necessary for suppressing aggregation of particles. (Molecular Therapy-Nucleic Acids (2012) 1, e37). Furthermore, the simultaneous presence of four types of lipids, including neutral lipids and sterols, in addition to these two types of lipids is extremely important for encapsulating nucleic acids and forming stable particles. Has been reported (Nanoscale. 2019 Nov 21; 11 (45): 21733-21739.).
- the lipid complex is, for example, 2- ⁇ 9-oxo-9-[(3-pentyloctyl) oxy] nonyl ⁇ dodecyl 1-methylpiperidine-4-carboxylate and DSPC, PEG2000-DMG, And at least one lipid selected from the group consisting of cholesterol and 2- ⁇ 9-oxo-9-[(3-pentyloctyl) oxy] nonyl ⁇ dodecyl 1-methylpiperidine-4- It may contain carboxylate, DSPC, PEG2000-DMG and cholesterol.
- the lipid complex is composed of cationic lipid / neutral lipid / polyethylene glycol-modified lipid / sterol as a lipid component, and the molar ratio of the lipid is, for example, 10 to 99/0 to 50 /. 0 to 10/0 to 50, 10 to 99/1 to 50 / 0.5 to 10/10 to 50, 40 to 70/1 to 20/0.5 to 2/20 to 40 or 40 to 70/0 to It may be 20 / 0.5 to 2/20 to 40.
- the molar ratio of cationic lipids / neutral lipids / polyethylene glycol modified lipids / sterols in the lipid complex is 30-90 / 0.1-20 / 0.01-10 / 0.1-70.
- the molar ratio of cationic lipid / triglyceride / polyethylene glycol modified lipid / sterol in the lipid complex is 40-70 / 3-15 / 0.1-3 / 15-60. In certain embodiments, the molar ratio of cationic lipids / triglycerides / polyethylene glycol modified lipids / sterols in the lipid complex is 60 / 10.5 / 1.5 / 28.
- the "average particle size" of the lipid complex refers to the Z-average particle size, and the average particle size is measured by a dynamic light scattering method.
- the average particle size (Z-average) of the lipid complex containing the double-stranded ribonucleic acid is not particularly limited, but may be, for example, 10 to 1000 nm, 30 to 500 nm, or 30 to 200 nm. In one embodiment, the average particle size of the lipid complex containing double-stranded ribonucleic acid is 100 nm or less. In certain embodiments, the average particle size of the lipid complex containing double-stranded ribonucleic acid is 65 nm or more and 100 nm or less.
- the average particle size of the lipid complex containing double-stranded ribonucleic acid is 80 nm or more and 100 nm or less, and in yet another embodiment, the average particle size of the lipid complex containing double-stranded ribonucleic acid is It is 85 nm or more and 100 nm or less.
- the pH of the lipid complex solution is 5.0 or less or 7.5 or more. In another embodiment, the pH of the solution of the lipid complex is 2.0 or more and 5.0 or less or 7.5 or more and 11.0 or less. In another embodiment, the pH of the solution of the lipid complex is 2.0 or more and 5.0 or less, 2.5 or more and 5.0 or less, 3.0 or more and 5.0 or less, 3.5 or more and 5. 0 or less, 4.0 or more and 5.0 or less, 4.5 or more and 5.0 or less, 7.5 or more and 11.0 or less, 7.5 or more and 10.5 or less, 7.5 or more and 10.0 or less, 7.
- the pH of the solution of the lipid complex is 7.5 or more and 8.5 or less.
- the average particle size of the lipid complex before storage is compared with the average particle size of the lipid complex after storage after a certain period of time, and the average particle size is determined. It can be judged by the magnitude of the fluctuation of.
- “before storage” may be, for example, immediately after the production of the pharmaceutical composition or, when the pH is adjusted, immediately after the pH adjustment.
- Examples of the storage conditions of the pharmaceutical composition according to the present embodiment include conditions that can be stored in a cold place or a refrigerator (refrigerated storage conditions), normal temperature or room temperature.
- the storage conditions for the pharmaceutical composition are 2-8 ° C.
- the storage condition of the pharmaceutical composition is 5 ° C.
- the storage condition for the pharmaceutical composition is 25 ° C.
- the storage stability of the pharmaceutical composition may be determined, for example, based on the average particle size of the lipid complex 2 weeks after the start of storage (after storage for 2 weeks), and 1 month after the start of storage (1 month storage). The judgment may be made based on the average particle size of the lipid complex (after), or may be judged based on the average particle size of the lipid complex 2 months after the start of storage (after storage for 2 months). It may be judged based on the average particle size of the lipid complex after 3 months (after storage for 3 months). In one embodiment, storage stability is good when the variation in the average particle size of the lipid complex after storage is within ⁇ 10% of the average particle size of the lipid complex before storage, for example.
- the storage stability is good when it is within ⁇ 8% of the average particle size of the lipid complex before storage, and it is the average particle size of the lipid complex before storage. If it is within ⁇ 5% in comparison, it may be judged that the storage stability is good. Specifically, for example, when the average particle size of the lipid complex two weeks after the start of storage is within ⁇ 10% of the average particle size of the lipid complex before storage, storage stability May be judged to be good.
- the storage stability of the pharmaceutical composition can be determined by increasing the average particle size, for example, the average particle size of the lipid complex after storage after a certain period of time is the lipid complex before storage.
- the storage stability is good, and if it is within + 8% of the average particle size of the lipid complex before storage, it may be judged that the storage stability is good. It may be judged that the storage stability is good, and if it is within + 5% of the average particle size of the lipid complex before storage, it may be judged that the storage stability is good. Specifically, for example, when the average particle size of the lipid complex two weeks after the start of storage is within + 10% of the average particle size of the lipid complex before storage, the storage stability is high. You may decide that it is okay.
- the encapsulation rate of siRNA in the lipid complex is such that the siRNA concentration measured by diluting with RNase Free Water using, for example, Quant-iT RiboGreen RNA Reagent (Invitrogen, Cat # R11491) is present in the LNP external solution.
- the encapsulation rate can be calculated by using the siRNA concentration measured by diluting with 1% Triton X-100 as the total siRNA concentration in the preparation (Kewal K. Jain, Drug Delivery System, Methods in Molecular Biologic, Vol. See also 1141: 109-120).
- the encapsulation rate calculated by the above method is higher than, for example, 80%, 85% or 90%. In one embodiment, the encapsulation rate of siRNA in the lipid complex is higher than 90%.
- a lipid complex encapsulating double-stranded ribonucleic acid in the pharmaceutical composition can be prepared by a method known in the art as described above.
- the lipid complex comprising double-stranded ribonucleic acid is a lipid solution comprising, for example, a cationic lipid and at least one lipid selected from the group consisting of neutral lipids, polyethylene glycol modified lipids, and sterols. And an acidic buffer containing double-stranded ribonucleic acid can be mixed.
- the lipid complex containing double-stranded ribonucleic acid may contain a cationic lipid and at least one lipid selected from the group consisting of neutral lipids, polyethylene glycol-modified lipids and sterols. ..
- the lipid complex containing the double-stranded ribonucleic acid is at least one selected from the group consisting of (I) cationic lipid, (II) neutral lipid, polyethylene glycol-modified lipid and sterol, for example.
- a lipid complex can be formed by changing the solubility of a lipid component containing and in a polar organic solvent-containing aqueous solution.
- the polar organic solvent include alcohols such as ethanol.
- a polar organic solvent containing (I) cationic lipid and at least one lipid selected from the group consisting of (II) neutral lipid, polyethylene glycol-modified lipid and sterol is dissolved.
- the aqueous solution and the aqueous solution containing (III) double-stranded ribonucleic acid are mixed to obtain a mixed solution.
- the concentration of the polar organic solvent in the polar organic solvent-containing aqueous solution is not particularly limited as long as the conditions for dissolving the lipid molecule are satisfied even after mixing with the aqueous solution containing double-stranded ribonucleic acid.
- the concentration of the polar organic solvent in the mixed solution obtained in the step (a) can be 0.1 to 60% by weight.
- An aqueous solution containing double-stranded ribonucleic acid can be obtained, for example, by dissolving double-stranded ribonucleic acid in an acidic buffer.
- the content of the polar organic solvent is reduced by adding water or the like to the above mixed solution. This allows the formation of lipid complexes. In order to efficiently form the lipid complex, it is preferable to sharply reduce the content of the polar organic solvent.
- the concentration of the polar organic solvent in the final polar organic solvent-containing aqueous solution in step (b) can be 0 to 5% by weight.
- the mixed solution obtained in step (a) may be subjected to dialysis to remove the polar organic solvent and the solvent may be replaced with a pharmaceutically acceptable medium. Since the content of the polar organic solvent in the solution decreases during the dialysis process, this allows the formation of a lipid complex.
- the method for producing the composition of the present embodiment it is possible to efficiently obtain a lipid complex in which double-stranded ribonucleic acid is encapsulated inside fine particles.
- Examples of the acidic buffer for dissolving the double-stranded ribonucleic acid include sulfuric acid buffer, phosphate buffer, phthalate buffer, tartaric acid buffer, citric acid buffer, formic acid buffer, oxalate buffer and acetate buffer.
- Examples of the solvent for dissolving the lipid include polar organic solvents such as alcohol, and may be, for example, ethanol, isopropanol, chloroform or t-butanol.
- the method for producing the pharmaceutical composition of the present embodiment can further include a step of adjusting the pH of the solution of the lipid complex.
- the pH of the solution is usually adjusted after the lipid complex contains double-stranded ribonucleic acid.
- the step may be, for example, a step of adjusting the pH of the solution of the lipid complex to 5.0 or less or 7.5 or more, and to 2.0 or more and 5.0 or less or 7.5 or more and 11.0 or less. It may be a step of adjusting, a step of adjusting to 2.0 or more and 5.0 or less, a step of adjusting to 7.5 or more and 11.0 or less, a step of adjusting to 7.5 or more and 10.0, 7.5 or more.
- the step may be a step of adjusting to 9.5 or less, a step of adjusting to 7.5 or more and 9.0 or less, or a step of adjusting to 7.5 or more and 8.5 or less.
- the step is the step of adjusting the solution of the lipid complex to a pH of 7.5 or more and 8.5 or less.
- the pH can be adjusted by a known method, for example, an acidic aqueous solution such as hydrochloric acid or a basic aqueous solution such as sodium hydroxide may be used, or phosphoric acid, citric acid, acetic acid, tartaric acid, or boric acid. It may be carried out by using a buffer solution (buffer) such as.
- an acidic aqueous solution such as hydrochloric acid or a basic aqueous solution such as sodium hydroxide
- phosphoric acid, citric acid, acetic acid, tartaric acid, or boric acid may be used, or phosphoric acid, citric acid, acetic acid, tartaric acid, or boric acid. It may be carried out by using a buffer solution (buffer) such as.
- buffer solution buffer
- the double-stranded ribonucleic acid contained in the pharmaceutical composition according to the present embodiment can inhibit the expression of complement C5 by RNAi.
- the pharmaceutical composition can include a pharmaceutically acceptable carrier in addition to the lipid complex comprising double-stranded ribonucleic acid.
- Examples of pharmaceutically acceptable carriers include liquid or solid fillers, diluents, excipients, manufacturing aids, solvent-encapsulated materials and the like.
- the pharmaceutical composition may be in a powder state in which the solvent has been removed by freeze-drying or the like, or in a liquid state.
- the pharmaceutical composition of one embodiment of the present invention is a powder composition containing the lipid complex of the above-described embodiment.
- the powder composition may be prepared by removing the solvent from the liquid composition (dispersion liquid) by, for example, filtration, centrifugation or the like, or by freeze-drying the dispersion liquid.
- the pharmaceutical composition is in powder form, it can be suspended or dissolved in a pharmaceutically acceptable medium before use and used as an injection.
- the pharmaceutical composition of one embodiment of the present invention is a liquid composition comprising the lipid complex of the above-described embodiment and a pharmaceutically acceptable medium. When the pharmaceutical composition is in a liquid state, it can be used as an injection as it is or suspended or dissolved in a pharmaceutically acceptable medium.
- RNAi can inhibit the expression of complement C5 in the subject.
- the required subjects are those who have developed a disease or disorder related to the expression or activity of the C5 gene, and those who are judged to have a high risk of developing the disease or disorder.
- the double-stranded ribonucleic acid contained in the pharmaceutical composition according to the present embodiment can suppress the expression of complement C5, so that the pharmaceutical composition according to the present embodiment is paroxysmal nocturnal. It may be useful in the treatment of hemoglobinuria (PNH) and atypical hemolytic urotoxicity syndrome (aHUS). That is, the present invention comprises, in other embodiments, administering to a subject a therapeutically effective amount of the pharmaceutical composition according to one embodiment of paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome. Includes treatment methods.
- PNH hemoglobinuria
- aHUS atypical hemolytic urotoxicity syndrome
- the subject to which the pharmaceutical composition according to the present embodiment is administered is not limited, and for example, the present invention can be used for human or non-human mammals (monkey, mouse, rat, rabbit, cow, horse, goat, etc.). it can.
- the method of administration of the pharmaceutical composition according to the present embodiment to a subject is not limited, and the health condition of the subject, the degree of disease, and the drug to be used in combination
- a person skilled in the art for example, a doctor can appropriately determine the type of the disease.
- the form of administration of the pharmaceutical composition according to one embodiment is not particularly limited, but may be parenteral administration, and examples thereof include intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, and intrathecal administration. Be done.
- the pharmaceutical composition according to one embodiment can be administered in an amount sufficient to inhibit complement C5, depending on the mode of administration.
- the dose of the pharmaceutical composition according to one embodiment may be, for example, 0.01 mg to 100 mg, 0.1 mg to 50 mg, or 0.3 mg to 10 mg per 1 kg of the body weight of the subject.
- the term "comprise” is intended to include the matters described (members, steps, elements or numbers, etc.) unless the context clearly requires a different understanding. It does not exclude the existence of other matters (members, steps, elements, numbers, etc.).
- the term “consist of” includes embodiments described by the terms “consist of” and / or “substantially consisting of”.
- first, second, etc. are used to describe various elements, but these elements should not be limited by these terms themselves. These terms are used only to distinguish one element from the other, for example, the first element is referred to as the second element, and similarly, the second element is the first element. Is possible without departing from the scope of the present invention.
- Example 1 Single dose in vitro screening (1)
- the sense strand and antisense strand shown in Table 2 were synthesized by the phosphoramidite method, and then double-stranded nucleic acids in which they were annealed were synthesized (GeneDesign, Inc.). The abbreviations for each sequence are shown in Table 1 below.
- the synthesized double-stranded nucleic acid has a hydroxy group at the 3'end instead of a phosphate group.
- RNAiMax (manufactured by Invitrogen, catalog number: 13778150) were diluted with Opti-MEM medium (manufactured by Gibco, catalog number: 31985562), and the final concentration was 3 nM.
- Opti-MEM medium manufactured by Gibco, catalog number: 31985562
- siRNA / RNAiMax mixed solution was prepared so as to have a double-stranded nucleic acid and 0.3% RNAiMax.
- siRNA / RNAiMax mixture 20 ⁇ L of siRNA / RNAiMax mixture was dispensed into 96-well culture plates, and each well was filled with Hep3B cells (obtained from ATCC), which is a cell line derived from human liver cancer, with a number of 20,000 cells / 80 ⁇ L / well. The seeds were sown so as to be, and cultured overnight at 37 ° C. under 5% CO 2 conditions. Using CellAmp (registered trademark) Direct RNA Prep Kit for PT-PCR (Real Time) (manufactured by Takara Bio Inc., catalog number: 3732) and Proteinase K (manufactured by Takara Bio Inc., catalog number: 9034), Takara Bio Inc.
- CellAmp registered trademark
- Direct RNA Prep Kit for PT-PCR Real Time
- Takara Bio Inc. catalog number: 3732
- Proteinase K manufactured by Takara Bio Inc., catalog number: 9034
- Template lysates for real-time PCR were prepared from cultured cells according to a company-provided protocol. Then, using PrimeScript (registered trademark) RT Master Mix (Perfect Real Time) (manufactured by Takara Bio Inc., catalog number: RR038A), cDNA was prepared according to the protocol provided by Takara Bio Inc. In addition, using Eagletac Universal Master Mix (ROX) (Roche Diagnostics, Catalog No .: 07260296190) and TaqMan probe (Applied Biosystems, C5: Hs00156197_m1; GAPDH: Hs02758991_g1), according to the protocol, GPDH: Hs02758991_g1.
- PrimeScript registered trademark
- RT Master Mix Perfect Real Time
- cDNA was prepared according to the protocol provided by Takara Bio Inc.
- ROX Eagletac Universal Master Mix
- TaqMan probe Applied Biosystems, C5: Hs00156197_m1; GAPDH: Hs02758991_g
- the Ct values of the target gene human C5 and the endogenous control gene human GAPDH were measured by a real-time PCR system (manufactured by Applied Biosystems).
- the C5 mRNA expression level was set to 100%, and the C5 mRNA residual rate (relative value) when each siRNA was introduced was measured by a calibration curve method. Calculated by As a negative control, Mock that does not intersect with any human gene was used.
- Example 2 Single dose in vitro screening (2) (Preparation of double-stranded nucleic acid)
- the sense strand and antisense strand shown in Table 4 were synthesized by the phosphoramidite method, and then double-stranded nucleic acids in which they were annealed were synthesized (GeneDesign, Inc.).
- Example 2 In vitro screening The test was carried out in the same manner as in Example 1 except that the siRNA / RNAiMax mixed solution was prepared so as to have a final concentration of 1 nM double-stranded nucleic acid and 0.3% RNAiMax, and the target gene human C5 and endogenous in Hep3B cultured cells were performed. The Ct value of the sex control gene human GAPDH was measured. In the same manner as in Example 1, the C5 mRNA expression level of Lifection only was set to 100%, and the C5 mRNA residual rate (relative value) when each siRNA was introduced was calculated.
- siRNA-LNP In vivo screening (sequence finding)]
- the siRNA shown in Table 6 was dissolved in 10 mM sodium citrate (pH 4.0) to prepare a diluted siRNA solution.
- Lipid nanoparticles were obtained by mixing the siRNA diluent and the lipid solution at a flow rate of 3 mL / min and 1 mL / min, respectively, with the ratio of siRNA to lipid being 0.1.
- the obtained LNP aqueous solution was replaced with PBS (pH 7.4) by dialysis using Float-A-Lyzer G2 (SPECTRUM, 100K MWCO). After dialysis, it was concentrated and sterilized by filtration and used in various experiments.
- the siRNA concentration and encapsulation rate were measured using a Quant-iT RiboGreen RNA Reagent (Invitrogen, Cat # R11491) (SiRNA concentration measured by diluting with RNase Free Water was used as the siRNA present in the LNP external solution, and 1% Triton X. The encapsulation rate was calculated by using the siRNA concentration measured by diluting with -100 as the total siRNA concentration in the preparation). The average particle size (Z-average) was measured with a particle size measuring device (Malvern, Zetasizer Nano ZS). The results of evaluating the pharmaceutical quality of the prepared LNP are shown in Table 7.
- Mouse C5 in plasma was quantified by the ELISA method. Specifically, on the assay plate (Nunc, Cat # 442404), the mouse anti-C5 antibody BB5.1 (Hycult, Cat # HM1073-FS) was added as a solid phase antibody to PBS (-) so as to have a final concentration of 2 ⁇ g / mL. Diluted with (Wako, # 045-29795), added and incubated overnight at 4 ° C.
- a goat anti-human C5 antibody (Quidel, Cat # A306) was diluted 4000 times with a blocking solution, added, and incubated at room temperature for 1 hour. After discarding the above antibody, wash with a washing solution 5 times, add HRP-labeled donkey anti-goat IgG (H + L) (Jackson Immunoresearch, Cat # 805-035-180) 40,000 times diluted with a blocking solution, and add at room temperature for 1 hour. Incubated. After discarding the above antibody, it was washed 5 times with a washing solution.
- TMB (3,3', 5,5'-tetramethylbenzidine) Peroxidase Substrate (KPL, Cat # 50-76-01), Peroxidase Substrate Solution B (KPL, Cat # 50-65-00), etc. were used as detection reagents. After mixing the amounts, the mixture was added to develop a color. After adding H 2 SO 4 (Wako, Cat # 198-09595) as a stop solution, the absorbance at 450 nm and 650 nm was measured. Table 9 shows the relative values of each sample when the C5 concentration in plasma 5 days after administration in the PBS-administered group was set to 100%.
- Example 4 In vitro screening
- the sense strand and antisense strand shown in Table 10 were synthesized by the phosphoramidite method, and then double-stranded nucleic acids in which they were annealed were synthesized (GeneDesign, Inc.).
- the test was carried out in the same manner as in Example 1 except that the siRNA / RNAiMax mixed solution was prepared so as to have a double-stranded nucleic acid having a final concentration of 0.003 to 10 nM and 0.3% RNAiMax, and the target gene in Hep3B cultured cells was obtained.
- the Ct values of human C5 and the endogenous control gene human GAPDH were measured.
- the C5 mRNA expression level of Lifection only was set to 100%, and the C5 mRNA residual rate (relative value) when each siRNA was introduced was calculated.
- Table 11 The results are shown in Table 11.
- Example 5 In vivo screening (overhang modification)]
- LNP Lipid nanoparticles encapsulating siRNA
- liver C5 mRNA survival rate (relative value) of the siRNA administration group was calculated by the comparative Ct method, assuming that the liver C5 mRNA survival rate on each measurement day in the PBS administration group was 100%. The results are shown in Table 14.
- Mouse C5 in plasma was quantified by the ELISA method. Specifically, on the assay plate (Nunc, Cat # 442404), the mouse anti-C5 antibody BB5.1 (Hycult, Cat # HM1073-FS) was added as a solid phase antibody to PBS (-) so as to have a final concentration of 2 ⁇ g / mL. Diluted with (Wako, # 045-29795), added and incubated overnight at 4 ° C.
- a goat anti-human C5 antibody (Quidel, Cat # A306) was diluted 4000 times with a blocking solution, added, and incubated at room temperature for 1 hour. After discarding the above antibody, wash with a washing solution 5 times, add HRP-labeled donkey anti-goat IgG (H + L) (Jackson Immunoresearch, Cat # 805-035-180) 40,000 times diluted with a blocking solution, and add at room temperature for 1 hour. Incubated. After discarding the above antibody, it was washed 5 times with a washing solution.
- TMB (3,3', 5,5'-tetramethylbenzidine) Peroxidase Substrate (KPL, Cat # 50-76-01) and Peroxidase Substrate Solution B (KPL, Cat # 50-65-00) were used as detection reagents. After mixing the amounts, the mixture was added to develop a color. After adding H 2 SO 4 (Wako, Cat # 198-09595) as a stop solution, the absorbances at 450 nm and 650 nm were measured. Table 15 shows the relative values of each sample when the C5 concentration contained in the plasma on the day before administration of the PBS administration group was set to 100%.
- Example 6 In vitro analysis (sequence walk)]
- the sense strand and antisense strand shown in Table 16 were synthesized by the phosphoramidite method, and then double-stranded nucleic acids in which they were annealed were synthesized (GeneDesign, Inc.).
- the C5 mRNA expression level of Lifection only was set to 100%, and the C5 mRNA residual rate (relative value) when each siRNA was introduced was calculated. The results are shown in Table 17.
- Example 7 Pharmacological test (hemolysis inhibitory effect)] (Preparation of siRNA-LNP) An LNP encapsulating siRNA was prepared in the same manner as in Example 3 except that siRNA shown in Table 18 was used. The results of evaluating the pharmaceutical quality of the prepared LNP are shown in Table 19.
- serum complement activity CH50 kit (Denka Seiken Co., Cat # 400,017) was used to prepare sheep erythrocytes according to the manufacturer's protocol to a 1.5x10 8 cells / mL. Subsequently, using the diluted solution attached to the serum complement titer CH50 kit, zymosan (Wako, Cat # 263-01491) was prepared to a concentration of 20 ⁇ g / mL. The sample serum was diluted 40-fold with a similar diluent. 50 ⁇ L each of the above sheep erythrocytes, zymosan, and diluted serum samples were mixed and incubated overnight at 37 ° C.
- Table 20 shows the values of each sample when the complement activity contained in the serum on the day before administration of each individual was set to 100%.
- Example 8 Pharmacological test (hemolysis inhibitory effect by a single dose)]
- An LNP encapsulating siRNA was prepared in the same manner as in Example 3 except that siRNA shown in Table 21 was used. The results of evaluating the pharmaceutical quality of the prepared LNP are shown in Table 22.
- serum complement activity CH50 kit (Denka Seiken Co., Cat # 400017) was used to prepare sheep erythrocytes according to the manufacturer's protocol to a 1.5x10 8 cells / mL. Subsequently, using the diluted solution attached to the serum complement titer CH50 kit, zymosan (Wako, Cat # 263-01491) was prepared to a concentration of 20 ⁇ g / mL. The sample serum was diluted 40-fold with a similar diluent. 50 ⁇ L each of the above sheep erythrocytes, zymosan, and diluted serum samples were mixed and incubated overnight at 37 ° C.
- Table 23 shows the values of each sample when the complement activity contained in the serum on the day before administration of each individual was set to 100%.
- the complement activity of one mouse in the 1 mg / kg administration group was excluded because it was considered to be an abnormal value. Therefore, the values in the 1 mg / kg administration group in Table 23 are the average values of three individual mice.
- the PBS-administered group, 0.3 mg / kg-administered group and 3 mg / kg-administered group in Table 23 are the average values of four mice. The results are also shown in FIG.
- Example 9 Pharmacological test (hemolysis inhibitory effect by biweekly administration)] (Preparation of siRNA-LNP) An LNP encapsulated with siRNA was prepared in the same manner as in Example 8.
- the blood collected on each collection day was placed in a tube containing a blood separating agent containing a coagulation promoter (IBL, Cat # 31203), centrifuged at 3000 rpm for 15 minutes, and the serum of the supernatant was collected and stored at -80 ° C. .. Then, the complement activity in serum was quantified by the following method. Specifically, serum complement activity CH50 kit (Denka Seiken Co., Cat # 400,017) was used to prepare sheep erythrocytes according to the manufacturer's protocol to a 1.5x10 8 cells / mL.
- serum complement activity CH50 kit (Denka Seiken Co., Cat # 400,017) was used to prepare sheep erythrocytes according to the manufacturer's protocol to a 1.5x10 8 cells / mL.
- zymosan (Wako, Cat # 263-01491) was prepared to a concentration of 20 ⁇ g / mL.
- the sample serum was diluted 40-fold with a similar diluent.
- 50 ⁇ L each of the above sheep erythrocytes, zymosan, and diluted serum samples were mixed and incubated overnight at 37 ° C.
- the assay plate was centrifuged at 2000 rpm for 10 minutes at room temperature, and then the absorbance of the supernatant at 405 nm was measured.
- Table 24 shows the values of each sample when the complement activity contained in the serum on the day before administration of each individual was set to 100%. The results are also shown in FIG.
- Example 10 Pharmacological test (hemolysis inhibitory effect by biweekly administration)] (Preparation of siRNA-LNP) An LNP encapsulated with siRNA was prepared in the same manner as in Example 8.
- the blood collected on each collection day was placed in a tube containing a blood separating agent containing a coagulation promoter (IBL, Cat # 31203), centrifuged at 3000 rpm for 15 minutes, and the serum of the supernatant was collected and stored at -80 ° C. .. Then, the complement activity in serum was quantified by the following method. Specifically, serum complement activity CH50 kit (Denka Seiken Co., Cat # 400 017) was used to prepare sheep erythrocytes according to the manufacturer's protocol to a 1.5x10 8 cells / mL.
- serum complement activity CH50 kit (Denka Seiken Co., Cat # 400 017) was used to prepare sheep erythrocytes according to the manufacturer's protocol to a 1.5x10 8 cells / mL.
- zymosan (Wako, Cat # 263-01491) was prepared to a concentration of 20 ⁇ g / mL.
- the sample serum was diluted 40-fold with a similar diluent.
- 50 ⁇ L each of the above sheep erythrocytes, zymosan, and diluted serum samples were mixed and incubated overnight at 37 ° C.
- the assay plate was centrifuged at 2000 rpm for 10 minutes at room temperature, and then the absorbance of the supernatant at 405 nm was measured.
- Table 25 shows the values of each sample when the complement activity contained in the serum on the day before administration of each individual was set to 100%. The results are also shown in FIG.
- Example 11 Pharmacological test (hemolysis inhibitory effect by administration every 3 weeks)]
- siRNA-LNP An LNP encapsulated with siRNA was prepared in the same manner as in Example 8.
- the blood collected on each collection day was placed in a tube containing a blood separating agent containing a coagulation promoter (IBL, Cat # 31203), centrifuged at 3000 rpm for 15 minutes, and the serum of the supernatant was collected and stored at -80 ° C. .. Then, the complement activity in serum was quantified by the following method. Specifically, serum complement activity CH50 kit (Denka Seiken Co., Cat # 400017) was used to prepare sheep erythrocytes according to the manufacturer's protocol to a 1.5x10 8 cells / mL.
- serum complement activity CH50 kit (Denka Seiken Co., Cat # 400017) was used to prepare sheep erythrocytes according to the manufacturer's protocol to a 1.5x10 8 cells / mL.
- zymosan (Wako, Cat # 263-01491) was prepared to a concentration of 20 ⁇ g / mL.
- the sample serum was diluted 40-fold with a similar diluent.
- 50 ⁇ L each of the above sheep erythrocytes, zymosan, and diluted serum samples were mixed and incubated overnight at 37 ° C.
- the assay plate was centrifuged at 2000 rpm for 10 minutes at room temperature, and then the absorbance of the supernatant at 405 nm was measured.
- Table 26 shows the values of each sample when the complement activity contained in the serum on the day before administration of each individual was set to 100%. The results are also shown in FIG.
- Example 12 Physical characteristic test
- SiRNA-008-34 shown in Table 4 was dissolved in 10 mM sodium citrate (pH 4.0) to prepare a diluted siRNA solution.
- 2- ⁇ 9-oxo-9- [(3-pentyloctyl) oxy] nonyl ⁇ dodecyl 1-methylpiperidin-4-carboxylate, DSPC (Nippon Seisei), Cholesterol (Dishman), MPEG2000-DMG (Nichiyu) was dissolved in ethanol at a molar ratio of 60 / 10.5 / 28 / 1.5 to prepare a lipid solution.
- LNP was obtained by mixing the siRNA diluent and the lipid solution at a flow rate of 3: 1.
- the obtained solution of LNP was replaced with PBS (pH 7.5) according to a conventional method, and then this LNP was concentrated.
- Hydrochloric acid or an aqueous sodium hydroxide solution was added to the concentrated solution of LNP to adjust the pH to 6.0 to 8.5. After pH adjustment, LNP was stored in a cold place.
- Table 27 shows the results of measuring the particle size of these LNPs with a particle size measuring device (Malvern, Zetasizer Nano ZS).
- Example 13 Physical characteristic test
- SiRNA-008-34 shown in Table 4 was dissolved in 10 mM sodium citrate (pH 4.0) to prepare a diluted siRNA solution.
- 2- ⁇ 9-oxo-9- [(3-pentyloctyl) oxy] nonyl ⁇ dodecyl 1-methylpiperidin-4-carboxylate, DSPC (Nippon Seisei), Cholesterol (Dishman), MPEG2000-DMG (Nichiyu) was dissolved in ethanol at a molar ratio of 60 / 10.5 / 28 / 1.5 to prepare a lipid solution.
- LNP was obtained by mixing the siRNA diluent and the lipid solution at a flow rate of 3: 1.
- the obtained solution of LNP was replaced with PBS (pH 7.5) according to a conventional method, and then this LNP was concentrated.
- Hydrochloric acid or an aqueous sodium hydroxide solution was added to the concentrated solution of LNP to adjust the pH to 6.5 to 8.5.
- pH adjustment LNP was stored in a cold place (5 ° C.).
- Table 28 shows the results of measuring the particle size of these LNPs with a particle size measuring device (NICOMP380).
- the properties of LNP at each pH were a homogeneous liquid exhibiting white to yellowish-white opalescent light, and did not change from immediately after pH adjustment to after storage for 1 month.
- Example 14 Physical characteristic test] (Particle size of siRNA-LNP when the pH of the LNP solution is changed) SiRNA-008-34 shown in Table 4 was dissolved in 10 mM sodium citrate (pH 4.0) to prepare a diluted siRNA solution.
- 2- ⁇ 9-oxo-9- [(3-pentyloctyl) oxy] nonyl ⁇ dodecyl 1-methylpiperidin-4-carboxylate, DSPC (Nippon Seisei), Cholesterol (Dishman), MPEG2000-DMG (Nichiyu) was dissolved in ethanol at a molar ratio of 60 / 10.5 / 28 / 1.5 to prepare a lipid solution.
- LNP was obtained by mixing the siRNA diluent and the lipid solution at a flow rate of 3: 1.
- the obtained solution of LNP was replaced with PBS (pH 7.5) according to a conventional method, and then this LNP was concentrated.
- Hydrochloric acid or an aqueous sodium hydroxide solution was added to the concentrated solution of LNP to adjust the pH to 6.5 to 8.5.
- pH adjustment LNP was stored in a cold place (5 ° C.).
- Table 29 shows the results of measuring the particle size of these LNPs with a particle size measuring device (NICOMP380).
- Example 15 Physical characteristic test
- SiRNA-008-34 shown in Table 4 was dissolved in 10 mM sodium citrate (pH 4.0) to prepare a diluted siRNA solution.
- 2- ⁇ 9-oxo-9- [(3-pentyloctyl) oxy] nonyl ⁇ dodecyl 1-methylpiperidin-4-carboxylate, DSPC (Nippon Seisei), Cholesterol (Dishman), MPEG2000-DMG (Nichiyu) was dissolved in ethanol at a molar ratio of 60 / 10.5 / 28 / 1.5 to prepare a lipid solution.
- LNP was obtained by mixing the siRNA diluent and the lipid solution at a flow rate of 3: 1.
- the obtained solution of LNP was replaced with PBS (pH 7.5) according to a conventional method, and then this LNP was concentrated.
- Hydrochloric acid or an aqueous sodium hydroxide solution was added to the concentrated solution of LNP to adjust the pH to 6.5 to 8.5.
- LNP was stored at room temperature (25 ° C.).
- Table 30 shows the results of measuring the particle size of these LNPs with a particle size measuring device (NICOMP380).
- Example 16 Physical characteristic test (Particle size of siRNA-LNP when the pH of the LNP solution is changed) SiRNA-008-34 shown in Table 4 was dissolved in 10 mM sodium citrate (pH 4.0) to prepare a diluted siRNA solution.
- LNP was obtained by mixing the siRNA diluent and the lipid solution at a flow rate of 3: 1.
- the obtained solution of LNP was replaced with PBS (pH 7.7) according to a conventional method, and then this LNP was concentrated. Then, the concentrated solution of LNP was sterilized by filtration after clarification filtration and concentration adjustment.
- This LNP solution is placed in a dialysis membrane, dialyzed at room temperature using each Briton Robinson (BR) buffer solution having a pH of 2.0 / 5.0 / 9.0 / 10.0 / 11.0, and LNP at each pH. A solution was obtained. After the completion of dialysis, the pH of each LNP solution was confirmed, and this LNP solution was designated as "immediately after pH adjustment". After adjusting the pH, the LNP solution was stored in a cold place (5 ° C.).
- Table 31 shows the results of measuring the particle size of these LNPs with a particle size measuring device (NICOMP380).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
[1] 脂質複合体を含む医薬組成物であって、
脂質複合体が、センス鎖及びアンチセンス鎖の組み合わせを有する二本鎖リボ核酸を含み、
センス鎖及びアンチセンス鎖の組み合わせが、
配列番号159に示すヌクレオチド配列からなるセンス鎖及び配列番号160に示すヌクレオチド配列からなるアンチセンス鎖、配列番号141に示すヌクレオチド配列からなるセンス鎖及び配列番号142に示すヌクレオチド配列からなるアンチセンス鎖、配列番号143に示すヌクレオチド配列からなるセンス鎖及び配列番号144に示すヌクレオチド配列からなるアンチセンス鎖、配列番号145に示すヌクレオチド配列からなるセンス鎖及び配列番号146に示すヌクレオチド配列からなるアンチセンス鎖、配列番号147に示すヌクレオチド配列からなるセンス鎖及び配列番号148に示すヌクレオチド配列からなるアンチセンス鎖、並びに配列番号153に示すヌクレオチド配列からなるセンス鎖及び配列番号154に示すヌクレオチド配列からなるアンチセンス鎖からなる群から選択され、
脂質複合体の溶液のpHが5.0以下又は7.5以上である、医薬組成物。
[2] 脂質複合体を含む医薬組成物であって、
脂質複合体が、配列番号145に示すヌクレオチド配列からなるセンス鎖及び配列番号146に示すヌクレオチド配列からなるアンチセンス鎖を有する二本鎖リボ核酸を含み、
脂質複合体の溶液のpHが5.0以下又は7.5以上である、医薬組成物。
[3] 脂質複合体の溶液のpHが2.0以上5.0以下又は7.5以上11.0以下である、[1]又は[2]に記載の医薬組成物。
[4] 脂質複合体の溶液のpHが5.0以下である、[1]又は[2]に記載の医薬組成物。
[5] 脂質複合体の溶液のpHが2.0以上5.0以下である、[1]又は[2]に記載の医薬組成物。
[6] 脂質複合体の溶液のpHが7.5以上である、[1]又は[2]に記載の医薬組成物。
[7] 脂質複合体の溶液のpHが7.5以上11.0以下である、[1]又は[2]に記載の医薬組成物。
[8] 脂質複合体の溶液のpHが7.5以上10.0以下である、[1]又は[2]に記載の医薬組成物。
[9] 脂質複合体の溶液のpHが7.5以上9.5以下である、[1]又は[2]に記載の医薬組成物。
[10] 脂質複合体の溶液のpHが7.5以上9.0以下である、[1]又は[2]に記載の医薬組成物。
[11] 脂質複合体の溶液のpHが7.5以上8.5以下である、[1]又は[2]に記載の医薬組成物。
[12] 脂質複合体の平均粒子径が100nm以下である、[1]~[11]のいずれかに記載の医薬組成物。
[13] 脂質複合体の平均粒子径が65nm以上100nm以下である、[1]~[12]のいずれかに記載の医薬組成物。
[14] 脂質複合体の平均粒子径が80nm以上100nm以下である、[1]~[12]のいずれかに記載の医薬組成物。
[15] 脂質複合体の平均粒子径が85nm以上100nm以下である、[1]~[12]のいずれかに記載の医薬組成物。
[16] 2週間保存後の脂質複合体の平均粒子径の変動が、保存前の脂質複合体の平均粒子径に対して10%以内である、[1]~[15]のいずれかに記載の医薬組成物。
[17] 2週間保存後の脂質複合体の平均粒子径の変動が、保存前の脂質複合体の平均粒子径に対して8%以内である、[1]~[15]のいずれかに記載の医薬組成物。
[18] 2週間保存後の脂質複合体の平均粒子径の変動が、保存前の脂質複合体の平均粒子径に対して5%以内である、[1]~[15]のいずれかに記載の医薬組成物。
[19] 1ヶ月保存後の脂質複合体の平均粒子径の変動が、保存前の脂質複合体の平均粒子径に対して10%以内である、[1]~[15]のいずれかに記載の医薬組成物。
[20] 1ヶ月保存後の脂質複合体の平均粒子径の変動が、保存前の脂質複合体の平均粒子径に対して8%以内である、[1]~[15]のいずれかに記載の医薬組成物。
[21] 1ヶ月保存後の脂質複合体の平均粒子径の変動が、保存前の脂質複合体の平均粒子径に対して5%以内である、[1]~[15]のいずれかに記載の医薬組成物。
[22] 3ヶ月保存後の脂質複合体の平均粒子径の変動が、保存前の脂質複合体の平均粒子径に対して10%以内である、[1]~[15]のいずれかに記載の医薬組成物。
[23] 3ヶ月保存後の脂質複合体の平均粒子径の変動が、保存前の脂質複合体の平均粒子径に対して8%以内である、[1]~[15]のいずれかに記載の医薬組成物。
[24] 3ヶ月保存後の脂質複合体の平均粒子径の変動が、保存前の脂質複合体の平均粒子径に対して5%以内である、[1]~[15]のいずれかに記載の医薬組成物。
[25] 平均粒子径の変動が、平均粒子径の増大である、[16]~[24]のいずれかに記載の医薬組成物。
[26] 医薬組成物の保存条件が2~8℃である、[16]~[25]のいずれかに記載の医薬組成物。
[27] 医薬組成物の保存条件が25℃である、[16]~[25]のいずれかに記載の医薬組成物。
[28] 脂質複合体が、
カチオン性脂質と、
中性脂質、ポリエチレングリコール修飾脂質、及びステロールからなる群から選択される少なくとも一種の脂質と
を含む、[1]~[27]のいずれかに記載の医薬組成物。
[29] 脂質複合体が、
カチオン性脂質、中性脂質、ポリエチレングリコール修飾脂質、及びステロールを含む、[1]~[28]のいずれかに記載の医薬組成物。
[30] カチオン性脂質が、
1-オキソ-1-(ウンデカン-5-イルオキシ)ノナデカン-10-イル-1-メチルピペリジン-4-カルボキシレート、1-((2-ブチルオクチル)オキシ)-1-オキソノナデカン-10-イル-1-メチルピペリジン-4-カルボキシレート、1-オキソ-1-(ウンデカン-5-イルオキシ)ヘプタデカン-8-イル-1-メチルピペリジン4-カルボキシレート、21-オキソ-21-(ウンデカン-5-イルオキシ)ヘンイコサン-10-イル-1-メチルピペリジン4-カルボキシレート、21-(オクタン-3-イルオキシ)-21-オキソヘンイコサン-10-イル-1-メチルピペリジン-4-カルボキシレート、1-((2-ブチルオクチル)オキシ)-1-オキソイコサン-10-イル-1-メチルピペリジン-4-カルボキシレート、(Z)-1-((2-ブチルノン-3-エン-1-イル)オキシ)-1-オキソイコサン-10-イル-1-メチルピペリジン-4-カルボキシレート、1-オキソ-1-((3-ペンチルオクチル)オキシ)イコサン-10-イル-1-メチルピペリジン-4-カルボキシレート、1-((3,4-ジプロピルヘプチル)オキシ)-1-オキソイコサン-10-イル-1-メチルピペリジン-4-カルボキシレート、1-((6-(ブチルジスルファニル)-3-(3-(ブチルジスルファニル)プロピル)ヘキシル)オキシ)-1-オキソイコサン-10-イル-1-メチルピペリジン-4-カルボキシレート、2-ブチルオクチル-10-((4-(ジメチルアミノ)ブタノイル)オキシ)イコサノエート、2-{9-[(2-ブチルオクチル)オキシ]-9-オキソノニル}ドデシル1-メチルピペリジン-4-カルボキシレート、2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレート、2-ノニル-11-オキソ-11-[(3-ペンチルオクチル)オキシ]ウンデシル 1-メチルピペリジン-4-カルボキシレート、ビス(3-ペンチルオクチル) 9―{[(1-メチルピペリジン-4-カルボニル)オキシ]メチル}ヘプタデカンジオエート、ジ[(Z)-2-ノネン-1-イル] 9―{[(1-メチルピペリジン-4-カルボニル)オキシ]メチル}ヘプタデカンジオエート、1-(2-オクチルシクロプロピル)ヘプタデカン-8-イル-1-メチルピペリジン-4-カルボキシレート、(3S)-2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピロリジン-3-カルボキシレート及び(3R)-2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピロリジン-3-カルボキシレートからなる群から選択される、
[28]又は[29]に記載の医薬組成物。
[31] カチオン性脂質が、
1-((2-ブチルオクチル)オキシ)-1-オキソイコサン-10-イル-1-メチルピペリジン-4-カルボキシレート、1-((2-ブチルオクチル)オキシ)-1-オキソノナデカン-10-イル-1-メチルピペリジン-4-カルボキシレート、2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレート、1-(2-オクチルシクロプロピル)ヘプタデカン-8-イル-1-メチルピペリジン-4-カルボキシレート、(3S)-2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピロリジン-3-カルボキシレート及び(3R)-2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピロリジン-3-カルボキシレートからなる群から選択される、
[28]~[30]のいずれかに記載の医薬組成物。
[32] カチオン性脂質が、2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレートである、[28]~[31]のいずれかに記載の医薬組成物。
[33] 中性脂質が、リン脂質又はセラミドである、[28]~[32]のいずれかに記載の医薬組成物。
[34] リン脂質が、
DOPE、POPE、HSPC、SOPC、POPC、EPC、DMPC、DPPC、DSPC、DAPC、DBPC、DLPC、DOPC、DOPG、DPPG、DSPG、DOPS、DOPE-MAL及びスフィンゴミエリンからなる群から選択される、
[33]に記載の医薬組成物。
[35] リン脂質が、
DOPE、HSPC、DPPC、DSPC及びDAPCからなる群から選択される、
[33]又は[34]に記載の医薬組成物。
[36] リン脂質が、DSPCである、[33]~[35]のいずれかに記載の医薬組成物。
[37] ポリエチレングリコール修飾脂質が、
PEG2000-DMG、PEG2000-DPG、PEG2000-DSG、PEG5000-DMG、PEG5000-DPG、PEG5000-DSG、PEG-cDMA、PEG-C-DOMG、PEG-DAG、PEG-DAA、PEG-リン脂質、PEG-コレステロール及びPEG-セラミド(Cer)からなる群から選択される、
[28]~[36]のいずれかに記載の医薬組成物。
[38] ポリエチレングリコール修飾脂質が、
PEG2000-DMG、PEG2000-DPG、PEG2000-DSG、PEG-cDMA及びPEG-C-DOMGからなる群から選択される、
[28]~[37]のいずれかに記載の医薬組成物。
[39] ポリエチレングリコール修飾脂質が、PEG2000-DMGである、[28]~[38]のいずれかに記載の医薬組成物。
[40] ステロールが、
コレステロール、ジヒドロコレステロール、ラノステロール、β-シトステロール、カンペステロール、スチグマステロール、ブラシカステロール、エルゴステロール、フコステロール及び3β-[N-(N’,N’-ジメチルアミノエチル)カルバモイル]コレステロール(DC-Chol)からなる群から選択される、
[28]~[39]のいずれかに記載の医薬組成物。
[41] ステロールが、
コレステロール、ジヒドロコレステロール、ラノステロール及びβ-シトステロールからなる群から選択される、
[28]~[40]のいずれかに記載の医薬組成物。
[42] ステロールが、コレステロールである、[28]~[41]のいずれかに記載の医薬組成物。
[43] 脂質複合体が、2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレート、DSPC、PEG2000-DMG及びコレステロールを含む、
[1]~[42]のいずれかに記載の医薬組成物。
[44] 脂質複合体におけるカチオン性脂質/中性脂質/ポリエチレングリコール修飾脂質/ステロールのモル比割が、30~90/0.1~20/0.01~10/0.1~70である、[1]~[43]のいずれかに記載の医薬組成物。
[45] 脂質複合体におけるカチオン性脂質/中性脂質/ポリエチレングリコール修飾脂質/ステロールのモル比割が、40~70/3~15/0.1~3/15~60である、[1]~[43]のいずれかに記載の医薬組成物。
[46] 脂質複合体におけるカチオン性脂質/中性脂質/ポリエチレングリコール修飾脂質/ステロールのモル比割が、60/10.5/1.5/28である、[1]~[43]のいずれかに記載の医薬組成物。
[47] 脂質複合体が、脂質ナノ粒子(LNP)である、[1]~[46]のいずれかに記載の医薬組成物。
[48] 脂質複合体が、センス鎖及びアンチセンス鎖の組み合わせを有する二本鎖リボ核酸を封入している、[1]~[47]のいずれかに記載の医薬組成物。
[49] [1]~[48]のいずれかに記載の医薬組成物であって、薬学的に許容される担体をさらに含む、医薬組成物。
[50] 発作性夜間ヘモグロビン尿症の治療用である、[1]~[49]のいずれかに記載の医薬組成物。
[51] 非典型溶血性尿毒症症候群の治療用である、[1]~[49]のいずれかに記載の医薬組成物。
[52] [1]~[49]のいずれかに記載の医薬組成物を、それを必要とする患者に投与することを含む、発作性夜間ヘモグロビン尿症の治療方法。
[53] [1]~[49]のいずれかに記載の医薬組成物を、それを必要とする患者に投与することを含む、非典型溶血性尿毒症症候群の治療方法。
[54] 発作性夜間ヘモグロビン尿症の治療における使用のための[1]~[49]のいずれかに記載の医薬組成物。
[55] 非典型溶血性尿毒症症候群の治療における使用のための[1]~[49]のいずれかに記載の医薬組成物。
[56] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、
脂質複合体の溶液のpHを5.0以下又は7.5以上に調整する工程を含む、製造方法。
[57] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、脂質複合体の溶液のpHを2.0以上5.0以下又は7.5以上11.0以下に調整する工程を含む、[56]に記載の製造方法。
[58] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、脂質複合体の溶液のpHを5.0以下に調整する工程を含む、[56]に記載の製造方法。
[59] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、脂質複合体の溶液のpHを2.0以上5.0以下に調整する工程を含む、[56]に記載の製造方法。
[60] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、脂質複合体の溶液のpHを7.5以上に調整する工程を含む、[56]に記載の製造方法。
[61] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、脂質複合体の溶液のpHを7.5以上11.0以下に調整する工程を含む、[56]に記載の製造方法。
[62] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、
脂質複合体の溶液のpHを7.5以上10.0以下に調整する工程を含む、[56]に記載の製造方法。
[63] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、
脂質複合体の溶液のpHを7.5以上9.5以下に調整する工程を含む、[56]に記載の製造方法。
[64] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、
脂質複合体の溶液のpHを7.5以上9.0以下に調整する工程を含む、[56]に記載の製造方法。
[65] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、
脂質複合体の溶液のpHを7.5以上8.5以下に調整する工程を含む、[56]に記載の製造方法。
[66] [1]~[55]のいずれかに記載の医薬組成物の製造方法であって、
(I)カチオン性脂質と(II)中性脂質、ポリエチレングリコール修飾脂質及びステロールからなる群より選択される少なくとも一種の脂質を含む有機溶媒と、
センス鎖及びアンチセンス鎖の組み合わせを有する二本鎖リボ核酸を含有する水溶液を混合して混合液を得る工程を含む、
[56]~[65]のいずれかに記載の製造方法。
[67] [1]~[55]に記載の医薬組成物の製造方法であって、
混合液から有機溶媒を除去する工程をさらに含む、[66]に記載の製造方法。
[68] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、
脂質複合体の溶液のpHを5.0以下又は7.5以上に調整する工程を含む、安定化方法。
[69] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、脂質複合体の溶液のpHを2.0以上5.0以下又は7.5以上11.0以下に調整する工程を含む、[68]に記載の安定化方法。
[70] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、脂質複合体の溶液のpHを5.0以下に調整する工程を含む、[68]に記載の安定化方法。
[71] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、脂質複合体の溶液のpHを2.0以上5.0以下に調整する工程を含む、[68]に記載の安定化方法。
[72] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、脂質複合体の溶液のpHを7.5以上に調整する工程を含む、[68]に記載の安定化方法。
[73] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、脂質複合体の溶液のpHを7.5以上11.0以下に調整する工程を含む、[68]に記載の安定化方法。
[74] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、
脂質複合体の溶液のpHを7.5以上10.0以下に調整する工程を含む、[68]に記載の安定化方法。
[75] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、
脂質複合体の溶液のpHを7.5以上9.5以下に調整する工程を含む、[68]に記載の安定化方法。
[76] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、
脂質複合体の溶液のpHを7.5以上9.0以下に調整する工程を含む、[68]に記載の安定化方法。
[77] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、
脂質複合体の溶液のpHを7.5以上8.5以下に調整する工程を含む、[68]に記載の安定化方法。
[78] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、
(I)カチオン性脂質と(II)中性脂質、ポリエチレングリコール修飾脂質及びステロールからなる群より選択される少なくとも一種の脂質を含む有機溶媒と、
センス鎖及びアンチセンス鎖の組み合わせを有する二本鎖リボ核酸を含有する水溶液を混合して混合液を得る工程を含む、
[68]~[77]のいずれかに記載の安定化方法。
[79] [1]~[55]のいずれかに記載の医薬組成物の安定化方法であって、
混合液から有機溶媒を除去する工程をさらに含む、[78]に記載の安定化方法。
[80] 医薬組成物の安定化方法が、医薬組成物中の脂質複合体の平均粒子径の変動を抑制する方法である、[68]~[79]のいずれかに記載の安定化方法。
[81] 平均粒子径の変動を抑制する方法が、平均粒子径の増大を抑制する方法である、[80]に記載の安定化方法。
(1)配列番号13に示すヌクレオチド配列からなるセンス鎖、及び配列番号14に示すヌクレオチド配列からなるアンチセンス鎖
(2)配列番号159に示すヌクレオチド配列からなるセンス鎖、及び配列番号160に示すヌクレオチド配列からなるアンチセンス鎖
(3)配列番号115に示すヌクレオチド配列からなるセンス鎖、及び配列番号116に示すヌクレオチド配列からなるアンチセンス鎖
(4)配列番号117に示すヌクレオチド配列からなるセンス鎖、及び配列番号118に示すヌクレオチド配列からなるアンチセンス鎖
(5)配列番号119に示すヌクレオチド配列からなるセンス鎖、及び配列番号120に示すヌクレオチド配列からなるアンチセンス鎖
(6)配列番号121に示すヌクレオチド配列からなるセンス鎖、及び配列番号122に示すヌクレオチド配列からなるアンチセンス鎖
(7)配列番号123に示すヌクレオチド配列からなるセンス鎖、及び配列番号124に示すヌクレオチド配列からなるアンチセンス鎖
(8)配列番号125に示すヌクレオチド配列からなるセンス鎖、及び配列番号126に示すヌクレオチド配列からなるアンチセンス鎖
(9)配列番号127に示すヌクレオチド配列からなるセンス鎖、及び配列番号128に示すヌクレオチド配列からなるアンチセンス鎖
(10)配列番号129に示すヌクレオチド配列からなるセンス鎖、及び配列番号130に示すヌクレオチド配列からなるアンチセンス鎖
(11)配列番号131に示すヌクレオチド配列からなるセンス鎖、及び配列番号132に示すヌクレオチド配列からなるアンチセンス鎖
(12)配列番号133に示すヌクレオチド配列からなるセンス鎖、及び配列番号134に示すヌクレオチド配列からなるアンチセンス鎖
(13)配列番号137に示すヌクレオチド配列からなるセンス鎖、及び配列番号138に示すヌクレオチド配列からなるアンチセンス鎖
(14)配列番号139に示すヌクレオチド配列からなるセンス鎖、及び配列番号140に示すヌクレオチド配列からなるアンチセンス鎖
(15)配列番号141に示すヌクレオチド配列からなるセンス鎖、及び配列番号142に示すヌクレオチド配列からなるアンチセンス鎖
(16)配列番号143に示すヌクレオチド配列からなるセンス鎖、及び配列番号144に示すヌクレオチド配列からなるアンチセンス鎖
(17)配列番号145に示すヌクレオチド配列からなるセンス鎖、及び配列番号146に示すヌクレオチド配列からなるアンチセンス鎖
(18)配列番号147に示すヌクレオチド配列からなるセンス鎖、及び配列番号148に示すヌクレオチド配列からなるアンチセンス鎖
(19)配列番号149に示すヌクレオチド配列からなるセンス鎖、及び配列番号150に示すヌクレオチド配列からなるアンチセンス鎖
(20)配列番号151に示すヌクレオチド配列からなるセンス鎖、及び配列番号152に示すヌクレオチド配列からなるアンチセンス鎖
(21)配列番号153に示すヌクレオチド配列からなるセンス鎖、及び配列番号154に示すヌクレオチド配列からなるアンチセンス鎖
5’-uGGuAuAuGuGuuGcuGAu-3’(配列番号13)
3’-AcCAuAuAcAcAAcGAcUA-5’(配列番号14)
本実施形態に係る医薬組成物は、二本鎖リボ核酸を含む脂質複合体を含む。一実施形態において脂質複合体は、I)上記二本鎖リボ核酸と、(II)カチオン性脂質と、(III)中性脂質、ポリエチレングリコール修飾脂質(PEG脂質)及びステロールからなる群より選択される少なくとも一種の脂質と、を含有する。本明細書において、脂質複合体としては、例えばLNP(脂質ナノ粒子)が挙げられるが、特にこれに限定されない。特定の実施形態において、医薬組成物は、二本鎖リボ核酸を封入している脂質複合体を含む。別の実施形態に係る医薬組成物は、二本鎖リボ核酸を含む脂質ナノ粒子を含む。
脂質複合体へ有効な分子を封入する方法としては、例えば、逆相蒸発法、Zwitterion(NaCl)水和法、カチオン性コア水和法及びエタノールとカルシウムを用いた方法(Biomembr.,1468、239-252(2000)も参照)等が挙げられる。上述のような該技術分野において公知の方法により、一実施形態に係る医薬組成物における二本鎖リボ核酸を封入した脂質複合体を調製することができる。
一実施形態に係る医薬組成物の投与の形態は特に限定されないが、非経口投与であってよく、例えば、静脈内投与、筋肉内投与、皮下投与、皮内投与及び髄腔内投与等が挙げられる。
(二本鎖核酸の調製)
表2に示すセンス鎖及びアンチセンス鎖をホスホロアミダイト法により合成し、その後、それらをアニーリングさせた二本鎖核酸を合成した(GeneDesign社)。各配列における略語は、以下の表1に示すとおりである。なお、合成した二本鎖核酸は3’末端にリン酸基ではなくヒドロキシ基を有している。
表2に記載の二本鎖核酸とトランスフェクション試薬Lipofectamine RNAiMax(Invitrogen社製、カタログ番号:13778150)を、Opti-MEM培地(Gibco社製、カタログ番号:31985062)で希釈し、最終濃度3nMの二本鎖核酸及び0.3%RNAiMaxとなるように、siRNA/RNAiMax混合液を調製した。20μLのsiRNA/RNAiMax混合液を各々96ウェルの培養プレートに分注し、各ウェルにヒト肝臓癌由来の細胞株であるHep3B細胞(ATCCより入手)を、20,000細胞数/80μL/ウェルとなるように播種し、37℃、5%CO2条件下で一晩培養した。CellAmp(登録商標)Direct RNA Prep Kit for PT-PCR(Real Time)(タカラバイオ株式会社製、カタログ番号:3732)及びProteinase K(タカラバイオ株式会社製、カタログ番号:9034)を用い、タカラバイオ株式会社提供のプロトコルに従って、培養細胞からリアルタイムPCR用鋳型ライセートを調製した。その後、PrimeScript(登録商標)RT Master Mix(Perfect Real Time)(タカラバイオ株式会社製、カタログ番号:RR036A)を用い、タカラバイオ株式会社提供のプロトコルに従って、cDNAを調製した。さらに、イーグルタック ユニバーサルマスターミックス(ROX)(Roche Diagnostics社製、カタログ番号:07260296190)及びTaqManプローブ(Applied Biosystems社製、C5:Hs00156197_m1;GAPDH:Hs02758991_g1)を用い、Applied Biosystems社提供のプロトコルに従って、ABI7900HTリアルタイムPCRシステム(Applied Biosystems社製)にて、標的遺伝子human C5及び内在性コントロール遺伝子human GAPDH(glyceraldehyde-3-phosphate dehydrogenase)のCt値を測定した。siRNAを添加せずにトランスフェクション試薬だけでHep3B細胞を処理した場合(Lipofection only)のC5 mRNA発現量を100%とし、各siRNAを導入した場合のC5 mRNA残存率(相対値)を検量線法により算出した。また陰性コントロールとしてヒトのいずれの遺伝子とも交差しないMockを用いた。
(二本鎖核酸の調製)
表4に示すセンス鎖及びアンチセンス鎖をホスホロアミダイト法により合成し、その後、それらをアニーリングさせた二本鎖核酸を合成した(GeneDesign社)。
最終濃度1nMの二本鎖核酸及び0.3%RNAiMaxとなるように、siRNA/RNAiMax混合液を調製した以外は、実施例1と同様に試験を行い、Hep3B培養細胞における標的遺伝子human C5及び内在性コントロール遺伝子human GAPDHのCt値を測定した。実施例1と同様に、Lipofection onlyのC5 mRNA発現量を100%とし、各siRNAを導入した場合のC5 mRNA残存率(相対値)を算出した。
(siRNA-LNPの調製)
表6に示すsiRNAを10mMクエン酸ナトリウム(pH4.0)に溶解し、siRNA希釈液とした。2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレート、DSPC(日本精化)、Cholesterol(日本精化)、MPEG2000-DMG(日油)を、モル比60/10.5/28/1.5の割合でエタノールに溶解し、脂質溶液とした。siRNAと脂質の比を重量比0.1とし、siRNA希釈液と脂質溶液をそれぞれ3mL/min、1mL/minの流速で混合することで、Lipid Nanoparticles(LNP)を得た。得られたLNP水溶液をFloat-A-Lyzer G2(SPECTRUM,100K MWCO)を用いて透析により外液をPBS(pH7.4)に置換した。透析後、濃縮及び濾過滅菌を行い、各種実験に用いた。siRNA濃度及び封入率は、Quant-iT RiboGreen RNA Reagent(Invitrogen, Cat#R11491)を用いて測定した(RNase Free Waterで希釈し測定したsiRNA濃度をLNP外液に存在するsiRNAとし、1%Triton X-100で希釈し測定したsiRNA濃度を製剤中の全siRNA濃度として封入率を算出した)。平均粒子径(Z-平均)は、粒子径測定装置(Malvern,Zetasizer Nano ZS)にて測定した。調製したLNPの製剤品質を評価した結果を表7に示す。
PBS又は表6に記載のsiRNAを封入したLNPをBALB/cマウス(オス,6週齢,n=3 per group)に0.1mg/kg siRNAとなるよう尾静脈内投与し、投与から5日後及び14日後に麻酔下で採血及び肝臓の採取を実施した。液体窒素にて凍結した肝臓から、RNeasy Plus Mini Kit(Quiagen,Cat#74106)を用い、製造業者のプロトコルに従って、Total RNAを精製した。その後、PrimeScript RT Master Mix(Perfect Real Time)(Takara, Cat#RR036A)を用い、製造業者のプロトコルに従って、cDNAを調製した。さらに、TaqMan(登録商標)Gene Expression Master Mix(Applied Biosystem,Cat#4369510)及びTaqManプローブ(Applied Biosystems,C5:Mm01336776_g1;GAPDH:Mm99999915_g1)を用い、製造業者のプロトコルに従って、ABI7500 Fast(Applied Biosystems)にて、標的遺伝子mouse C5、及び内在性コントロール遺伝子mouse GAPDHのCt値を測定した。PBS投与群における投与5日後の肝臓C5 mRNA残存率を100%とし、各siRNA投与群の肝臓C5 mRNA残存率(相対値)を比較Ct法により算出した。結果を表8に示す。
表10に示すセンス鎖及びアンチセンス鎖をホスホロアミダイト法により合成し、その後、それらをアニーリングさせた二本鎖核酸を合成した(GeneDesign社)。最終濃度0.003~10nMの二本鎖核酸及び0.3%RNAiMaxとなるように、siRNA/RNAiMax混合液を調製した以外は、実施例1と同様に試験を行い、Hep3B培養細胞における標的遺伝子human C5及び内在性コントロール遺伝子human GAPDHのCt値を測定した。実施例1と同様に、Lipofection onlyのC5 mRNA発現量を100%とし、各siRNAを導入した場合のC5 mRNA残存率(相対値)を算出した。結果を表11に示す。
(siRNA-LNPの調製)
表12に記載のsiRNAを使用した以外は実施例3と同様に、siRNAを封入した脂質ナノ粒子(LNP)を調製した。調製したLNPの製剤品質を評価した結果を表13に示す。
PBS又は表12に記載のsiRNAを封入したLNPをBALB/cマウス(オス,6週齢,n=3 per group)に0.3mg/kg siRNAとなるよう尾静脈内投与し、投与から5日後、14日後及び21日後に麻酔下で採血及び肝臓の採取を実施した。液体窒素にて凍結した肝臓から、RNeasy Plus Mini Kit (Quiagen,Cat#74106)を用い、製造業者のプロトコルに従って、Total RNAを精製した。その後、PrimeScript RT Master Mix(Perfect Real Time)(Takara,Cat#RR036A)を用い、製造業者のプロトコルに従って、cDNAを調製した。さらに、TaqMan(登録商標)Gene Expression Master Mix(Applied Biosystem,Cat# 4369510)及びTaqManプローブ(Applied Biosystems,C5:Mm01336776_g1;GAPDH:Mm99999915_g1)を用い、製造業者のプロトコルに従って、ABI7500 Fast(Applied Biosystems)にて、標的遺伝子mouse C5、及び内在性コントロール遺伝子mouse GAPDHのCt値を測定した。PBS投与群における各測定日の肝臓C5 mRNA残存率を100%とし、siRNA投与群の肝臓C5 mRNA残存率(相対値)を比較Ct法により算出した。結果を表14に示す。
表16に示すセンス鎖及びアンチセンス鎖をホスホロアミダイト法により合成し、その後、それらをアニーリングさせた二本鎖核酸を合成した(GeneDesign社)。実施例1と同様に、Lipofection onlyのC5 mRNA発現量を100%とし、各siRNAを導入した場合のC5 mRNA残存率(相対値)を算出した。結果を表17に示す。
(siRNA-LNPの調製)
表18に示すsiRNAを用いた以外は実施例3と同様にsiRNAを封入したLNPを調製した。調製したLNPの製剤品質を評価した結果を表19に示す。
PBS又は表18に記載のsiRNAを封入したLNPをBALB/cマウス(オス,6週齢,n=3 per group)に1-3mg/kg siRNAとなるよう尾静脈内投与し、投与から5日後及び9日後に麻酔下で採血を実施した。各採材日に採取した血液を凝固促進剤入り血液分離剤入りチューブ(IBL、Cat#31203)に入れ、3000rpm,15分間遠心した後、上清の血清を採取し、-80℃に保存した。その後、血清中の補体活性を以下の方法で定量した。具体的には、血清補体価CH50キット(デンカ生研株式会社、Cat#400017)を用い、製造業者のプロトコルに従いヒツジ赤血球を1.5x108 cells/mLとなるように調製した。以後、血清補体価CH50キットに付属の希釈液を用いて、zymosan(Wako,Cat#263-01491)を20μg/mLとなるように調製した。同様の希釈液を用いて、サンプル血清を40倍に希釈した。上記のヒツジ赤血球、zymosan、及び希釈した血清サンプルをそれぞれ50μLずつ混合し、37℃で一晩インキュベートした。翌日、アッセイプレートを2000rpm,10分間室温で遠心した後、上清の405nmの吸光度を測定した。各個体の投与前日の血清中に含まれる補体活性を100%としたときの各サンプルの値を表20に示す。
(siRNA-LNPの調製)
表21に示すsiRNAを用いた以外は実施例3と同様にsiRNAを封入したLNPを調製した。調製したLNPの製剤品質を評価した結果を表22に示す。
PBS又は表21に記載のsiRNAを封入したLNPをBALB/cマウス(オス,7週齢,n=4 per group)に0.3、1及び3mg/kg siRNAとなるよう尾静脈内投与した。投与前日(表23における「投与1日前」)、投与から7日後、13日後、20日後及び27日後に麻酔下で採血を実施した。各採材日に採取した血液を凝固促進剤入り血液分離剤入りチューブ(IBL、Cat#31203)に入れ、3000rpm,15分間遠心した後、上清の血清を採取し、-80℃に保存した。その後、血清中の補体活性を以下の方法で定量した。具体的には、血清補体価CH50キット(デンカ生研株式会社、Cat#400017)を用い、製造業者のプロトコルに従いヒツジ赤血球を1.5x108 cells/mLとなるように調製した。以後、血清補体価CH50キットに付属の希釈液を用いて、zymosan(Wako,Cat#263-01491)を20μg/mLとなるように調製した。同様の希釈液を用いて、サンプル血清を40倍に希釈した。上記のヒツジ赤血球、zymosan、及び希釈した血清サンプルをそれぞれ50μLずつ混合し、37℃で一晩インキュベートした。翌日、アッセイプレートを2000rpm,10分間室温で遠心した後、上清の405nmの吸光度を測定した。各個体の投与前日の血清中に含まれる補体活性を100%としたときの各サンプルの値を表23に示す。1mg/kg投与群のマウス1個体の補体活性は異常値と考えられることから除外した。したがって、表23における1mg/kg投与群の値はマウス3個体の平均値である。表23におけるPBS投与群、0.3mg/kg投与群及び3mg/kg投与群はマウス4個体の平均値である。結果を図3にも示す。
(siRNA-LNPの調製)
実施例8と同様にsiRNAを封入したLNPを調製した。
実施例8におけるPBS又は表21に記載のsiRNAを封入したLNPをBALB/cマウス(オス,7週齢,n=4 per group)に0.3、1及び3mg/kg siRNAとなるよう隔週で尾静脈内投与した。投与前日(表24における「投与1日前」)、投与から7日後、13日後、20日後及び27日後に麻酔下で採血を実施した。各採材日に採取した血液を凝固促進剤入り血液分離剤入りチューブ(IBL、Cat#31203)に入れ、3000rpm,15分間遠心した後、上清の血清を採取し、-80℃に保存した。その後、血清中の補体活性を以下の方法で定量した。具体的には、血清補体価CH50キット(デンカ生研株式会社、Cat#400017)を用い、製造業者のプロトコルに従いヒツジ赤血球を1.5x108 cells/mLとなるように調製した。以後、血清補体価CH50キットに付属の希釈液を用いて、zymosan(Wako,Cat#263-01491)を20μg/mLとなるように調製した。同様の希釈液を用いて、サンプル血清を40倍に希釈した。上記のヒツジ赤血球、zymosan、及び希釈した血清サンプルをそれぞれ50μLずつ混合し、37℃で一晩インキュベートした。翌日、アッセイプレートを2000rpm,10分間室温で遠心した後、上清の405nmの吸光度を測定した。各個体の投与前日の血清中に含まれる補体活性を100%としたときの各サンプルの値を表24に示す。結果を図4にも示す。
(siRNA-LNPの調製)
実施例8と同様にsiRNAを封入したLNPを調製した。
実施例8におけるPBS又は表21に記載のsiRNAを封入したLNPをBALB/cマウス(オス,7週齢,n=4 per group)に0.3、1及び3mg/kg siRNAとなるよう隔週で尾静脈内投与した。投与前日(表25における「投与1日前」)、投与から7日後、13日後、20日後、27日後、34日後、41日後、48日後及び55日後に麻酔下で採血を実施した。各採材日に採取した血液を凝固促進剤入り血液分離剤入りチューブ(IBL、Cat#31203)に入れ、3000rpm,15分間遠心した後、上清の血清を採取し、-80℃に保存した。その後、血清中の補体活性を以下の方法で定量した。具体的には、血清補体価CH50キット(デンカ生研株式会社、Cat#400017)を用い、製造業者のプロトコルに従いヒツジ赤血球を1.5x108 cells/mLとなるように調製した。以後、血清補体価CH50キットに付属の希釈液を用いて、zymosan(Wako,Cat#263-01491)を20μg/mLとなるように調製した。同様の希釈液を用いて、サンプル血清を40倍に希釈した。上記のヒツジ赤血球、zymosan、及び希釈した血清サンプルをそれぞれ50μLずつ混合し、37℃で一晩インキュベートした。翌日、アッセイプレートを2000rpm,10分間室温で遠心した後、上清の405nmの吸光度を測定した。各個体の投与前日の血清中に含まれる補体活性を100%としたときの各サンプルの値を表25に示す。結果を図5にも示す。
(siRNA-LNPの調製)
実施例8と同様にsiRNAを封入したLNPを調製した。
実施例8におけるPBS又は表21に記載のsiRNAを封入したLNPをBALB/cマウス(オス,7週齢,n=4 per group)に0.3、1及び3mg/kg siRNAとなるよう3週間毎に尾静脈内投与した。投与前日(表26における「投与1日前」)、投与から7日後、13日後、20日後、27日後、34日後、41日後、48日後及び55日後に麻酔下で採血を実施した。各採材日に採取した血液を凝固促進剤入り血液分離剤入りチューブ(IBL、Cat#31203)に入れ、3000rpm,15分間遠心した後、上清の血清を採取し、-80℃に保存した。その後、血清中の補体活性を以下の方法で定量した。具体的には、血清補体価CH50キット(デンカ生研株式会社、Cat#400017)を用い、製造業者のプロトコルに従いヒツジ赤血球を1.5x108 cells/mLとなるように調製した。以後、血清補体価CH50キットに付属の希釈液を用いて、zymosan(Wako,Cat#263-01491)を20μg/mLとなるように調製した。同様の希釈液を用いて、サンプル血清を40倍に希釈した。上記のヒツジ赤血球、zymosan、及び希釈した血清サンプルをそれぞれ50μLずつ混合し、37℃で一晩インキュベートした。翌日、アッセイプレートを2000rpm,10分間室温で遠心した後、上清の405nmの吸光度を測定した。各個体の投与前日の血清中に含まれる補体活性を100%としたときの各サンプルの値を表26に示す。結果を図6にも示す。
(LNP溶液のpHを変動させた際のsiRNA-LNPの粒子径)
表4に示すsiRNA-008-34を10mMクエン酸ナトリウム(pH4.0)に溶解し、siRNA希釈液とした。2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレート、DSPC(日本精化)、Cholesterol(Dishman)、MPEG2000-DMG(日油)を、モル比60/10.5/28/1.5の割合でエタノールに溶解し、脂質溶液とした。siRNA希釈液と脂質溶液を3:1の流速で混合することで、LNPを得た。得られたLNPの溶液を、常法に従いPBS(pH7.5)に置換し、その後、このLNPを濃縮した。LNPの濃縮液に塩酸又は水酸化ナトリウム水溶液を添加してpH6.0~8.5に調整した。pH調整後、LNPは冷所で保存した。
(LNP溶液のpHを変動させた際のsiRNA-LNPの粒子径)
表4に示すsiRNA-008-34を10mMクエン酸ナトリウム(pH4.0)に溶解し、siRNA希釈液とした。2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレート、DSPC(日本精化)、Cholesterol(Dishman)、MPEG2000-DMG(日油)を、モル比60/10.5/28/1.5の割合でエタノールに溶解し、脂質溶液とした。siRNA希釈液と脂質溶液を3:1の流速で混合することで、LNPを得た。得られたLNPの溶液を、常法に従いPBS(pH7.5)に置換し、その後、このLNPを濃縮した。LNPの濃縮液に塩酸又は水酸化ナトリウム水溶液を添加してpH6.5~8.5に調整した。pH調整後、LNPは冷所(5℃)で保存した。
(LNP溶液のpHを変動させた際のsiRNA-LNPの粒子径)
表4に示すsiRNA-008-34を10mMクエン酸ナトリウム(pH4.0)に溶解し、siRNA希釈液とした。2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレート、DSPC(日本精化)、Cholesterol(Dishman)、MPEG2000-DMG(日油)を、モル比60/10.5/28/1.5の割合でエタノールに溶解し、脂質溶液とした。siRNA希釈液と脂質溶液を3:1の流速で混合することで、LNPを得た。得られたLNPの溶液を、常法に従いPBS(pH7.5)に置換し、その後、このLNPを濃縮した。LNPの濃縮液に塩酸又は水酸化ナトリウム水溶液を添加してpH6.5~8.5に調整した。pH調整後、LNPは冷所(5℃)で保存した。
(LNP溶液のpHを変動させた際のsiRNA-LNPの粒子径)
表4に示すsiRNA-008-34を10mMクエン酸ナトリウム(pH4.0)に溶解し、siRNA希釈液とした。2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレート、DSPC(日本精化)、Cholesterol(Dishman)、MPEG2000-DMG(日油)を、モル比60/10.5/28/1.5の割合でエタノールに溶解し、脂質溶液とした。siRNA希釈液と脂質溶液を3:1の流速で混合することで、LNPを得た。得られたLNPの溶液を、常法に従いPBS(pH7.5)に置換し、その後、このLNPを濃縮した。LNPの濃縮液に塩酸又は水酸化ナトリウム水溶液を添加してpH6.5~8.5に調整した。pH調整後、LNPは室温(25℃)で保存した。
(LNP溶液のpHを変動させた際のsiRNA-LNPの粒子径)
表4に示すsiRNA-008-34を10mMクエン酸ナトリウム(pH4.0)に溶解し、siRNA希釈液とした。2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレート、DSPC(Lipoid)、Cholesterol(Dishman)、MPEG2000-DMG(日油)を、モル比60/10.5/28/1.5の割合でエタノールに溶解し、脂質溶液とした。siRNA希釈液と脂質溶液を3:1の流速で混合することで、LNPを得た。得られたLNPの溶液を、常法に従いPBS(pH7.7)に置換し、その後、このLNPを濃縮した。そして、LNPの濃縮液を清澄ろ過及び濃度調整した後に、ろ過滅菌した。このLNP溶液を透析膜に入れ、pH2.0/5.0/9.0/10.0/11.0の各ブリトンロビンソン(BR)緩衝液を用いて室温にて透析し、各pHのLNP溶液を得た。透析終了後、各LNP溶液のpHを確認し、このLNP溶液を「pH調整直後」とした。pH調整後、LNP溶液は冷所(5℃)で保存した。
Claims (20)
- 脂質複合体を含む医薬組成物であって、
脂質複合体が、配列番号145に示すヌクレオチド配列からなるセンス鎖及び配列番号146に示すヌクレオチド配列からなるアンチセンス鎖を有する二本鎖リボ核酸を含み、
脂質複合体の溶液のpHが5.0以下又は7.5以上である、医薬組成物。 - 脂質複合体の溶液のpHが2.0以上5.0以下又は7.5以上11.0以下である、請求項1に記載の医薬組成物。
- 脂質複合体の溶液のpHが7.5以上10.0以下である、請求項1に記載の医薬組成物。
- 脂質複合体の平均粒子径が100nm以下である、請求項1~3のいずれか一項に記載の医薬組成物。
- 脂質複合体の平均粒子径が65nm以上100nm以下である、請求項1~3のいずれか一項に記載の医薬組成物。
- 脂質複合体の平均粒子径が80nm以上100nm以下である、請求項1~3のいずれか一項に記載の医薬組成物。
- 2週間保存後の脂質複合体の平均粒子径の変動が、保存前の脂質複合体の平均粒子径に対して10%以内である、請求項1~6のいずれか一項に記載の医薬組成物。
- 脂質複合体の平均粒子径の変動が、脂質複合体の平均粒子径の増大である、請求項7に記載の医薬組成物。
- 脂質複合体が、
カチオン性脂質と、
中性脂質、ポリエチレングリコール修飾脂質、及びステロールからなる群から選択される少なくとも一種の脂質と
を含む、請求項1~8のいずれか一項に記載の医薬組成物。 - カチオン性脂質が、2-{9-オキソ-9-[(3-ペンチルオクチル)オキシ]ノニル}ドデシル 1-メチルピペリジン-4-カルボキシレートである、請求項9に記載の医薬組成物。
- 脂質複合体が、脂質ナノ粒子(LNP)である、請求項1~10のいずれか一項に記載の医薬組成物。
- 脂質複合体が、センス鎖及びアンチセンス鎖の組み合わせを有する二本鎖リボ核酸を封入している、請求項1~11のいずれか一項に記載の医薬組成物。
- 発作性夜間ヘモグロビン尿症の治療用である、請求項1~12のいずれか一項に記載の医薬組成物。
- 非典型溶血性尿毒症症候群の治療用である、請求項1~12のいずれか一項に記載の医薬組成物。
- 請求項1~14のいずれか一項に記載の医薬組成物の製造方法であって、
脂質複合体の溶液のpHを5.0以下又は7.5以上に調整する工程を含む、製造方法。 - 脂質複合体の溶液のpHを2.0以上5.0以下又は7.5以上11.0以下に調整する工程を含む、請求項15に記載の製造方法。
- 請求項1~14のいずれか一項に記載の医薬組成物の安定化方法であって、
脂質複合体の溶液のpHを5.0以下又は7.5以上に調整する工程を含む、安定化方法。 - 脂質複合体の溶液のpHを2.0以上5.0以下又は7.5以上11.0以下に調整する工程を含む、請求項17に記載の安定化方法。
- 医薬組成物の安定化方法が、医薬組成物中の脂質複合体の平均粒子径の変動を抑制する方法である、請求項17又は請求項18に記載の安定化方法。
- 平均粒子径の変動を抑制する方法が、平均粒子径の増大を抑制する方法である、請求項19に記載の安定化方法。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080083622.9A CN114867484A (zh) | 2019-12-26 | 2020-12-24 | 含有抑制补体c5的表达的双链核糖核酸的药物组合物 |
CA3163264A CA3163264A1 (en) | 2019-12-26 | 2020-12-24 | Pharmaceutical composition containing double-stranded ribonucleic acid inhibiting expression of complement c5 |
EP20906116.7A EP4052710A4 (en) | 2019-12-26 | 2020-12-24 | PHARMACEUTICAL COMPOSITION CONTAINING DOUBLE STRANDED RIBONUCLEIC ACID FOR INHIBITING EXPRESSION OF COMPLEMENT C5 |
AU2020413311A AU2020413311A1 (en) | 2019-12-26 | 2020-12-24 | Pharmaceutical composition containing double-stranded ribonucleic acid inhibiting expression of complement C5 |
US17/768,283 US20240050462A1 (en) | 2019-12-26 | 2020-12-24 | Pharmaceutical composition containing double-stranded ribonucleic acid inhibiting expression of complement c5 |
BR112022010742A BR112022010742A2 (pt) | 2019-12-26 | 2020-12-24 | Composição farmacêutica contendo ácido ribonucleico de fita dupla que inibe a expressão de c5 complementar |
JP2021534788A JP6961860B1 (ja) | 2019-12-26 | 2020-12-24 | 補体c5の発現を抑制する二本鎖リボ核酸を含む医薬組成物 |
KR1020227018069A KR20220122608A (ko) | 2019-12-26 | 2020-12-24 | 보체 c5의 발현을 저해하는 이중 가닥 리보핵산을 함유하는 약제학적 조성물 |
MX2022006514A MX2022006514A (es) | 2019-12-26 | 2020-12-24 | Composicion farmaceutica que contiene un acido ribonucleico de doble hebra que inhibe la expresion de c5 de complemento. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019236918 | 2019-12-26 | ||
JP2019-236918 | 2019-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021132462A1 true WO2021132462A1 (ja) | 2021-07-01 |
Family
ID=76573276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/048441 WO2021132462A1 (ja) | 2019-12-26 | 2020-12-24 | 補体c5の発現を抑制する二本鎖リボ核酸を含む医薬組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240050462A1 (ja) |
EP (1) | EP4052710A4 (ja) |
JP (1) | JP6961860B1 (ja) |
KR (1) | KR20220122608A (ja) |
CN (1) | CN114867484A (ja) |
AU (1) | AU2020413311A1 (ja) |
BR (1) | BR112022010742A2 (ja) |
CA (1) | CA3163264A1 (ja) |
MX (1) | MX2022006514A (ja) |
WO (1) | WO2021132462A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014160129A2 (en) | 2013-03-14 | 2014-10-02 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2015105131A1 (ja) | 2014-01-09 | 2015-07-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | カチオン性脂質 |
WO2016104580A1 (ja) | 2014-12-26 | 2016-06-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | カチオン性脂質 |
WO2017222016A1 (ja) | 2016-06-24 | 2017-12-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | カチオン性脂質 |
WO2020085456A1 (ja) * | 2018-10-26 | 2020-04-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 補体c5の発現を抑制する二本鎖リボ核酸 |
-
2020
- 2020-12-24 MX MX2022006514A patent/MX2022006514A/es unknown
- 2020-12-24 CN CN202080083622.9A patent/CN114867484A/zh active Pending
- 2020-12-24 BR BR112022010742A patent/BR112022010742A2/pt unknown
- 2020-12-24 JP JP2021534788A patent/JP6961860B1/ja active Active
- 2020-12-24 US US17/768,283 patent/US20240050462A1/en active Pending
- 2020-12-24 WO PCT/JP2020/048441 patent/WO2021132462A1/ja active Application Filing
- 2020-12-24 EP EP20906116.7A patent/EP4052710A4/en active Pending
- 2020-12-24 KR KR1020227018069A patent/KR20220122608A/ko active Search and Examination
- 2020-12-24 AU AU2020413311A patent/AU2020413311A1/en active Pending
- 2020-12-24 CA CA3163264A patent/CA3163264A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014160129A2 (en) | 2013-03-14 | 2014-10-02 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
JP2016518331A (ja) * | 2013-03-14 | 2016-06-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 補体成分C5iRNA組成物及びその使用方法 |
WO2015105131A1 (ja) | 2014-01-09 | 2015-07-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | カチオン性脂質 |
WO2016104580A1 (ja) | 2014-12-26 | 2016-06-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | カチオン性脂質 |
WO2017222016A1 (ja) | 2016-06-24 | 2017-12-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | カチオン性脂質 |
WO2020085456A1 (ja) * | 2018-10-26 | 2020-04-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 補体c5の発現を抑制する二本鎖リボ核酸 |
Non-Patent Citations (13)
Title |
---|
"GenBank", Database accession no. NM-001735.2 |
BALL, R. L. ET AL.: "Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization", INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 12, 2017, pages 305 - 315, XP055405289 * |
BIOMEMBR., vol. 1468, 2000, pages 239 - 252 |
HOWARD JF JR ET AL., MUSCLE NERVE, vol. 48, no. 1, July 2013 (2013-07-01), pages 76 - 84 |
KEWAL K. JAIN, DRUG DELIVERY SYSTEM, METHODS IN MOLECULAR BIOLOGY, vol. 1141, pages 109 - 120 |
LEGENDRE CM ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 368, no. 23, 6 June 2013 (2013-06-06), pages 2169 - 2181 |
MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 1, 2012, pages e37 |
NANOSCALE, vol. 11, no. 45, 21 November 2019 (2019-11-21), pages 21733 - 21739 |
NUCLEIC ACID RESEARCH, vol. 35, no. 10, 2007, pages 3287 - 96 |
PETER HILLMEN ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 350, no. 6, 5 February 2004 (2004-02-05), pages 552 - 559 |
PITTOCK SJ ET AL., THE LANCET NEUROLOGY, vol. 12, no. 6, June 2013 (2013-06-01), pages 554 - 562 |
See also references of EP4052710A4 |
STEGALL MD ET AL., AMERICAN JOURNAL OF TRANSPLANTATION, vol. 11, no. 11, November 2011 (2011-11-01), pages 2405 - 2413 |
Also Published As
Publication number | Publication date |
---|---|
AU2020413311A1 (en) | 2022-06-16 |
MX2022006514A (es) | 2022-07-11 |
EP4052710A4 (en) | 2024-02-28 |
CN114867484A (zh) | 2022-08-05 |
BR112022010742A2 (pt) | 2022-08-16 |
CA3163264A1 (en) | 2021-07-01 |
KR20220122608A (ko) | 2022-09-02 |
JP6961860B1 (ja) | 2021-11-05 |
JPWO2021132462A1 (ja) | 2021-12-23 |
EP4052710A1 (en) | 2022-09-07 |
US20240050462A1 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6725776B1 (ja) | 補体c5の発現を抑制する二本鎖リボ核酸 | |
EP1842558A1 (en) | Composition for inhibiting expression of target gene | |
WO2017135397A1 (ja) | 補体b因子の発現を抑制するアンチセンスオリゴヌクレオチド | |
WO2018117253A1 (ja) | 補体b因子の発現を抑制する核酸 | |
WO2021132462A1 (ja) | 補体c5の発現を抑制する二本鎖リボ核酸を含む医薬組成物 | |
EP3594345A1 (en) | Nucleic acid capable of inhibiting expression of masp2 | |
US20170247701A1 (en) | Nucleic acid capable of inhibiting expression of beta-2gpi | |
JP6918197B2 (ja) | 脂質複合体を含む医薬組成物及び脂質ナノ粒子を含む医薬組成物 | |
RU2781954C1 (ru) | Двухцепочечная рибонуклеиновая кислота, ингибирующая экспрессию компонента комплемента c5 | |
CN112771163B (zh) | 能够遏制补体c5的表达的双链核糖核酸 | |
TW201903149A (zh) | 抑制apcs之表現的核酸 | |
JP5335673B2 (ja) | 子宮癌、乳癌、及び膀胱癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬 | |
JP2022523320A (ja) | 加齢黄斑変性の処置のためのオリゴヌクレオチドおよび方法 | |
WO2010110314A1 (ja) | 核酸を含有する肺高血圧症治療剤 | |
WO2024002320A1 (zh) | 一种抑制b7-h3基因表达的干扰rna及其应用 | |
US20200069721A1 (en) | Staufen1 agents and associated methods | |
EP2837389A1 (en) | Medicinal composition for treating infarction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2021534788 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20906116 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 17768283 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 3163264 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022010742 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020413311 Country of ref document: AU Date of ref document: 20201224 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020906116 Country of ref document: EP Effective date: 20220601 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022114885 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112022010742 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220601 |